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ABSTRACT 
 
NAJLA TASLIM. ROLE OF NICOTINIC ACETYLCHOLINE RECEPTOR SUBTYPES α4β2 
AND α7 IN NICOTINE-ETHANOL INTERACTION AND CROSS-TOLERANCE: 
FUNCTIONAL CORRELATION WITH CEREBELLAR NITRIC OXIDE. (Under the Direction 
of Dr. M.S. Dar) Department of Pharmacology and Toxicology, June 2010 
 
The prevalent co-abuse of alcohol and tobacco products results in higher morbidity 
and mortality rates than those caused by either drug alone, thus posing a serious health 
problem. Understanding the interactive relationship between nicotine and ethanol might 
lead to effective strategies for the treatment of co-addiction. This dissertation project was 
designed to investigate the role of two nicotinic-acetylcholine-receptor (nAChR) subtypes 
(i.e. α4β2 and α7) on nicotine’s attenuation of ethanol ataxia and its functional correlation 
with alterations in cerebellar nitric oxide concentration. Expression levels of cerebellar α4β2 
and α7 subtypes were also determined immunohistochemically.  
Ethanol (2g/kg;i.p.)-induced ataxia was assessed by Rotorod in stereotaxically 
cannulated CD-1 male mice following the acute or repeated intracerebellar (ICB) 
microinfusions of α4β2- and α7-selective agonists, RJR-2403 and PNU-282987.  Acute RJR-
2403 (31, 62, 125ng), and PNU-282987 (25ng, 250ng, 2.5µg), dose-dependently reduced 
ethanol ataxia. Pretreatment with potent α4β2 [Dihydro-β-erythroidine (DHβE)] and α7 
[Methyllycaconitine (MLA)]-subtype–selective antagonists prevented RJR-2403 and PNU-
282987’s attenuation of ethanol ataxia, respectively. Both antagonists also offset nicotine’s 
reduction of ethanol ataxia, confirming the contribution of α4β2 and α7 subtype in ethanol 
ataxia.  There was no tonic role of either subtype in ethanol ataxia. Additionally, ICB α4β2 
and α7 subtype antisense treatment data correspond with agonist-induced behavioral 
responses. Animals repeatedly microinfused with RJR- 2403 or PNU-282987 became 
tolerant to ethanol ataxia. The observed cross-tolerance was faster in onset and longer in 
duration with PNU-282987 than RJR-2403.  Pretreatment with DHβE and MLA, prevented 
the development of cross-tolerance.  
The cerebellar nitrite+nitrate (NOx) levels were significantly enhanced and reduced 
following acute/repeated RJR- 2403/PNU-282987 microinfusion and acute ethanol 
 
 
injection, respectively. Pretreatment with RJR- 2403 or PNU-282987 followed by ethanol 
prevented the ethanol-induced decrease in NOx concentration in both acute and repeated 
treatment paradigms, thus correlating the decrease in NOx concentration with ataxia and 
elevation with attenuation of ataxia.  Both α4β2 and α7 subtypes exhibited high 
immunoreactivity in Purkinje, however, expression in molecular and granular cell layers 
was sparse.  Overall, the results of the project support the role of α4β2 and α7 subtypes in 
the functional interaction between nicotine and acute ethanol ataxia, with NO-cGMP 
signaling as a participating factor. 
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CHAPTER ONE: INTRODUCTION 
 
General Introduction and Purpose of the Project 
Nicotine and ethanol are the most widely consumed psychoactive drugs worldwide.  
Epidemiological studies reported that 80-90% of alcoholics regularly smoke tobacco 
(Pomerleau et al., 1997; Romberger and Grant, 2004).  Similarly, the consumption of 
alcohol is 10 times more prevalent in tobacco smokers than nonsmokers (DiFranza and 
Guerrera, 1990). This strongly suggests that those who abuse these drugs may be more 
vulnerable to ethanol and nicotine addiction than non-abusers. It is also evident that a 
strong functional relationship may exist between the two drugs. The societal cost of the 
compulsive co-abuse of these drugs is in billions of dollars to treat smoking related 
morbidities as well as ethanol associated illnesses. The grave consequences resulting 
from the co-addiction of nicotine and ethanol necessitates an understanding of the 
underlying mechanisms in the functional interaction to enable possible development of 
effective therapeutic intervention. Because epidemiological data provided strong 
circumstantial evidence for a functional interaction between these drugs, we thought it 
would be interesting to investigate motor behavioral consequences of co-administration of 
nicotine and ethanol in a male CD-1 mouse model. Within the central nervous system, 
functional interactions between nicotine and ethanol have been well documented (Hays et 
al., 1999; Anthony et al. 2000; Meyerhoff et al., 2006). However, the precise 
pharmacological mechanism(s) of interaction between nicotine and ethanol are not well 
understood and appear complex. Previously, we have demonstrated that direct 
microinfusion of intracerebellar (ICB) nicotine markedly antagonizes ethanol-induced motor 
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impairment dose-dependently in a glutamate-nitric oxide-cGMP sensitive manner.  
Interestingly, repeated ICB microinfusion of nicotine completely abolished acute ethanol 
ataxia indicating development of cross-tolerance between the two psychoactive drugs (Al-
Rejaie and Dar, 2006b, c). This dissertation research, therefore, represented a logical 
extension of our previous work and was aimed to determine the role of specific nicotinic 
nAChRs subtypes i.e. α4β2 and α7 subtypes in the functional interaction between 
acute/chronic nicotine and alcohol-indcued ataxia as the test response and possible 
participation of cerebellar NO signaling.  
The cerebellum was selected for studying the nicotine and ethanol interaction 
because it is the key motor brain area for coordinating motor activity and an important site 
for the action of nicotine to attenuate ethanol-indcued ataxia (Al-Rejaie and Dar, 2006 a,b).  
A number of nAChR subtypes such as α3β2, α4β2, α3β4, α4β4, α6, α5 and most notably α4β2 
and α7 have been detected in the cerebellum in humans and rodents (Graham et al., 2002; 
Turner and Kellar, 2005).   Review of the current literature favors a predominant role of 
α4β2 and α7 subtypes in mediating several behavioral actions of nicotine (Damaj et al., 
1995a; Picciotto et al., 1998; Chan et al., 2007) and ethanol (Le et al., 2000; Bowers et al., 
2005; Steensland et al., 2007).  Therefore, this constituted the primary reason for the 
hypothesis that nAChR α4β2 and α7 subtypes are involved in the behavioral interaction 
between acute nicotine and ethanol, the development of cross-tolerance between chronic 
nicotine and acute ethanol ataxia and their overall functional correlation with the cerebellar 
nitric oxide (NO) concentration.   Support for this hypothesis was provided when direct ICB 
microinfusion of acute nicotine or agonist of nAChR α4β2- and α7-selective subtypes 
markedly and dose-dependently attenuated ethanol-induced motor impairment.  The 
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attenuation of ethanol ataxia by ICB nicotine, the α4β2-selective agonist,  RJR-2403, and 
the α7-selective agonist, PNU-282987, was virtually abolished following ICB pretreatment 
with DHβE, an α4β2-selective antagonist, and methyllycaconitine, an α7-selective 
antagonist, respectively.  This observation confirmed the participation of the nAChR 
subtypes, α4β2 and α7, in the functional interaction between acute nicotine and ethanol 
ataxia.  Intracerebellar treatment with antisense oligonucleotides for the α4β2 and α7 
subtypes abolished the attenuating effect of RJR-2403 and PNU-282987 on acute ethanol 
ataxia by knocking down the expression of proteins for both subtypes.  In the control 
animals pretreated similarly with missense oligonucleotides against α4β2 and α7 subtypes 
mRNA, the normal attenuating effect of RJR-2403 and PNU-282987 was observed. The 
results of antisense and missense experiments provided further confirmation that α4β2 and 
α7 subtypes play a role in the functional interaction of nicotine and ethanol.    
This dissertation research also demonstrated that repeated ICB microinfusion of 
various doses of RJR-2403 and PNU-282987 on acute ethanol ataxia resulted in the 
development of cross-tolerance between nicotine and acute ethanol ataxia in a dose 
dependent manner. The optimal cross-tolerance was observed in 5-day nicotine/RJR-2403 
ICB treatment group and it lasted for 48 hours.  The dose dependency of the development 
of cross-tolerance indicated the absence of nicotine receptor desensitization up to 5-day 
treatment but significant nAChRs desensitization was observed following 7-day 
nicotine/RJR-2403 treatment. The peak of cross-tolerance was observed only after 1-day 
PNU-282987 treatment and lasted for 72 hours.  The results of the chronic studies were in 
agreement with the acute experimental data and confirmed the involvement of α4β2 and α7 
nAChR subtypes in the nicotine and ethanol interaction. Repeated pretreatment with the 
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α4β2- and α7- selective antagonists, DHβE and methyllycaconitine, respectively, blocked 
the development of the cross-tolerance indicating the mediating role of α4β2- and α7 
subtypes. Despite several reports regarding distribution of nAChR subtypes, controversy 
still exists regarding whether α4β2 and α7 subtypes are present in cerebellum (Gotti and 
Clementi, 2004; Nashmi and Lester, 2006). We attempted to immunohistochemically 
determine the comparative cerebellar distribution of most predominant nAChR α4β2 and α7 
subtypes (Paterson and Nordberg, 2000; Gotti and Clementi, 2004; Nashmi and Lester, 
2006). We have previously shown that sodium nitroprusside (a NO donor), and isoliquiritin 
(an activator of guanyl cyclase) augmented nicotine’s ability to counter ethanol ataxia 
whereas S-methylisothiourea (an inhibitor of inducible NO synthase), and ODQ (1H 
[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one) (an inhibitor of guanyl cyclase) diminished 
nicotine’s attenuating effect on ethanol ataxia suggesting participation of NO signaling.  
Consequently, the dissertation research measured cerebellar concentrations of NO 
following intracerebellar microinfusion of acute/repeated RJR-2403 and PNU-282987, α4β2 
and α7 subtype agonists, respectively, in the presence or absence of acute alcohol. 
Information regarding the participation of specific nAChR subtypes in the alcohol – nicotine 
interaction defined from the proposed research may ultimately lead to the development of 
therapeutic agents (e.g. agonists and antagonists of nAChRs subtype(s)) which may 
permit: (i) to curb factors which drive smokers to seek alcohol kick or vice versa 
(antagonist drug of nAChRs subtype(s); and (ii) to attenuate the degree of motor 
impairment due to alcohol consumption (agonist drug of nAChRs subtype(s). 
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Nicotine History 
Historical records show that the ancient tobacco plant “nicotinna tabacum” was 
used for more than 10000 years by Central, North and South Americans for ceremonial 
and religious purposes (Gately, 2001). Medicinally, the tobacco plant was known to heal 
wounds and suppress appetite. To exploit medicinal benefits, the plant was snuffed, 
chewed, smoked and drunk as a liquid brew (Gately, 2001; Kuper et al., 2002). During the 
14-16th century, the tobacco plant was introduced globally followed by a booming era of 
cigar and cigarette smoking. Despite awareness of serious health risks associated with its 
use, smoking of tobacco, which is a highly addictive substance, continues to be wide 
spread. Addiction to tobacco is largely due to its principle alkaloid, nicotine. Along with 
nicotine, tobacco smoke contains 4,000 highly toxic and carcinogenic substances 
including, organic solvents, heavy metals, carbon monoxide etc (Haustein, 2003). 
Currently, nicotine in the form of smoking is ranked as the most exorbitantly 
consumed substance of abuse. Statistically, about 30% of the American population (70-80 
million) indulged in nicotine abuse in the form of smoking cigarette, cigars, pipes and 
chewing gums.  In the US alone, tobacco consumption is responsible for nearly 400,000 
deaths/year due to lung cancer, stroke, cardiovascular and respiratory diseases, with lung 
cancer being the third leading cause of preventable deaths  (Mokdad et al., 2004)(Table 
1). 
Nicotinic Acetylcholine Receptors (nAChRs) 
The physiological and pharmacological actions of nicotine are mediated by specific 
nicotinic acetylcholine receptors (nAChRs): the well characterized members of the 
superfamily of ligand gated ion channels. Intrinsically, nAChRs are pentameric ligand  
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TABLE 1:  Annual causes of deaths in the United States (Mokdad et al., 2004) 
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gated ion channels that are composed of different combinations of distinct subunits e.g. 
one of the eight α (α2- α9) and, of three β (β2- β4), each encoded by a different gene. The 
assembly of distinct α  and β  subunits constitutes, in various combinations, a number of 
homomeric and heteromeric nAChRs subtypes (Paterson & Nordberg, 2000; Nott and  
Levin et al. 2006)  i.e. α2- α4 and β2/ β4 receptor subunits form a pentameric structures only 
in association with other subunits while α7-α9 can assemble together to form homomeric 
nAChRs subtypes of identical subunits. Examples of heteromeric receptors are α2β2, α2β4, 
α3β4, α3β2, α4β2, α2β3 and of homomeric subtypes are α7, α9. The pentameric subunits 
assemble around a central ion pore with an M2 region lining the central pore of the 
receptor (Paterson & Nordberg, 2000). 
Not only both homomeric and heteromeric nAChR subtypes are distinct in terms of 
their pharmacological and physiological behavior but individual receptor subtypes in each 
category have their own unique characteristics. This signifies the contribution of each 
receptor subunit  (α or β) in determining the overall properties of the receptor subtype 
(Papke et al., 1993; Wang et al, 1996). Ubiquitously distributed, neuronal nAChRs are 
differentiated by their kinetic properties, ligand binding characteristics, localization, subunit 
composition, pharmacological and functional properties and cation permeability. Of all the 
nAChR subtypes, those composed of α4β2 and α7 exhibit highest nicotine sensitivity with 
ED50% values of 1-5µM and 40µM, respectively (Gotti et al. 1997).   
Structure of Nicotinic Acetylcholine Receptors 
The Topography of nAChRs as revealed by earlier crystallographic studies have 
identified the following components of individual subunits of the nAChRs :1) an 
extracellular hydrophilic amino terminus (-NH2-) of 200 amino acids bearing agonist 
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binding sites, 2) a compact hydrophobic domain consisting of four transmembrane (TM) 
spanning domains, M1-M4; 3) a selectivity filter which lies between the M3-M4 domains; 
and 4) an intracellular hydrophobic loop between domains M3-M4  that contains 
phosphorylation sites for serine/threonine kinases (Fig. 1) (Galzi & Changeux, 1995; 
Corringer et al., 2000). The homomeric nAChRs subtypes exhibit five acetylcholine binding 
sites , one on each α subunit at the interface between two adjoining α subunits, while 
heteromeric receptor subtypes with two  α and 3 β subunits have only two ligand binding 
sites at the interface between  α and β subunits. As these acetylcholine binding sites have 
functionally cooperative interaction, it requires five and two ligand molecules to activate 
homomeric and heteromeric  nAChRs, respectively (Changeux & Edelstein, 1998; 
Corringer et al., 2002).  Besides, nAChRs bear dihydropyridine, steroid and allosteric 
activator and inhibitor sites which offer enormous opportunities for pharmacological 
manipulation of the nAChRs. Among the allosteric activators are tacrine, benzoquinonium, 
acetylcholinesterase inhibitors such as physostigmine and neostigmine (Svensson & 
Nordberg, 1996; Schrattenholz et al., 1996). The allosteric binding site in α4β2 is 
presumably located on α-subunit. These compounds act to enhance channel opening 
frequency (Pereira et al., 1993) and ion conductance as well as to  upregulate binding sites 
(Svensson & Nordberg, 1996). The allosteric inhibitors include, ethanol, phencyclidine,  
MK-801, chlorpromazine, local anesthetics and barbiturates. The binding of allosteric 
inhibitors to their distinct sites (high affinity, low affinity sites) does not prevent ligand 
binding to acetylcholine sites but reduces the open time of channel (Nagata et al., 1996). 
Besides, nAChRs bear dihydropyridine, steroid and allosteric activator and inhibitor sites  
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FIGURE 1: General structure of an ionotropic neuronal nicotinic acetylcholine receptor 
(nAChR) (Bate & Gardiner, 1999) 
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which offer enormous opportunities for pharmacological manipulation of the nAChRs. 
Among the allosteric activators are tacrine, benzoquinonium, acetylcholinesterase 
inhibitors such as physostigmine and neostigmine (Svensson & Nordberg, 1996; 
Schrattenholz et al., 1996). The allosteric binding site in α4β2 is presumably located on α-
subunit. These compounds act to enhance channel opening frequency (Pereira et al., 
1993) and ion conductance as well as to  upregulate binding sites (Svensson & Nordberg, 
1996). The allosteric inhibitors include, ethanol, phencyclidine, MK-801, chlorpromazine, 
local anesthetics and barbiturates. The binding of allosteric inhibitors to their distinct sites 
(high affinity, low affinity sites) does not prevent ligand binding to acetylcholine sites but 
reduces the open time of channel (Nagata et al., 1996).  
Distribution of Nicotinic Acetylcholine Receptor  Subtypes in the CNS 
As yet, the distribution of nAChRs has been thoroughly explored in invertebrates, 
primates, rodents and humans in the  and peripheral nervous system as well as in non-
neuronal sites including skin, lung, immune cells and the cardiovascular system (Paterson 
& Nordberg, 2000; Gotti & Clementi, 2004; Nashmi & Lester, 2006). The current 
knowledge of cellular/subcellular distribution of nAChRs is based on 
immunohistochemistry, immunoprecipitation, immunoblotting and radioligand binding 
techniques. The relative selectivity or specificity of certain ligands or antibodies for one 
nAChR subtype over other subtypes forms the basis for the identification of different 
nAChRs subtypes. For instance, [3H]-cytisine displays the highest affinity for the α4β2 
subtype and [3H]-methyllycaconitine or [125I]-α-BTX for α7 subtypes and so are used for 
labeling of their respective subtypes (Ward et al., 1990). [3H]-nicotine and [3H]-epibatidine 
are rather nonselective ligands and bind α4β2, and other subtypes, notably α3β2, α3β4 
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(Flores et al., 1997; Zoli et al., 1998) in low doses and α7 at high doses (Ward et al., 1990). 
Since α4β2   and α7 subtypes bind nicotine with high (nM) and low affinity (µM) respectively, 
these subtypes are termed as high and low affinity subtypes. 
In humans, [3H]-nicotine binding sites were found distributed densely in the 
thalamus and caudate-putamen, moderately in the cortex (occipital, fronto-parietal), 
sparsely in the temporal cortex, hippocampus and cerebellum while no binding sites were 
shown in the hypothalamus, pineal gland and medial habenula. Conversely, [125I]-α-BTX 
binding was rich in hippocampus, nucleus reticularis, pontine nucleus, area broca and 
inferior olivary nucleus, moderate in the hypothalamus, pons and medulla and low in the 
cortex and cerebellum (Gotti and Clementi, 2004). Thus, low but detectable levels of [3H]-
nicotine and [125I]-α-BTX binding was found in the human cerebellum. The cerebellar 
granular layer contained more [3H]-nicotine bindings sites than the molecular layer (Court 
et al., 2000); while the molecular layer has more [125I]-α-BTX binding sites than the 
granular layer (Aubert et al.,1992). Similar observations were made with 
immunohistochemical studies that demonstrated that Purkinje cells express a high density 
of α4, α7 and moderate to weak levels of α3, α4, α6, β2, β4  while granule cells contained α4, 
β2, β4 but not α3 in human cerebellum (Graham et al., 2002).   
In rodents, the generalized profile of nAChR distribution is not markedly different 
from those of human and primates, though some species related discrepancies exist. [3H ]-
nicotine binding sites are highly abundant in the thalamus, cerebral cortex (layer III/IV), 
interpeduncular nucleus and superior colliculus (Clarke et al., 1985); moderately abundant 
in the parietal cortex, cingulate cortex, subiculum, substantia nigra, optic nerve dorsal 
raphe, laterodorsal tegmental nucleus and retrospenial cortex; and low in the medial 
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septum, nucleus accumbens, caudate putamen, hippocampus and olfactory tubercle 
(Marks et al., 1992). α-BTX-binding was concentrated in the hippocampus, hypothalamus 
and cortical layers I/VI (Clarke et al., 1985). However, the distribution of nAChR subtypes 
in the cerebellum has been controversial. While Decker et al. (1999) have found a 
moderate expression of [3H ]-nicotine binding sites and nil for [125I]-α-BTX binding sites 
(see Table 2), Nashmi and Lester (2006) did not detect any nAChR binding in rat 
cerebellum.  
However, some recent studies, investigating cellular and subcellular details, do 
support the existence of nAChRs in the cerebellum (Nakayama et al., 1997,1998). For 
example, a high α4 transcript level had been detected in the Purkinje and granule layers 
while less intense signal was noted in the molecular layer (Nakayama et al., 1998). 
Immunohistochemica studies, using α4 selective monoclonal antibodies in adult Wistar rats 
have also revealed a similar pattern of distribution of α4 receptor protein in the molecular, 
Purkinje and granule layers, with the strongest signal in the Purkinje cell layer. The 
subcellular regions immunostained for α4 subunits in Purkinje cells include the soma, 
plasma membrane, rough endoplasmic reticulum, perikarya, axo-somatic synapse and 
extrasynaptic sites as well as the granule cell somatic membranes (Nakayama et al., 
1998). Other studies also support the existence of α4, β2 immunoreactivity in Purkinje, 
granule and deep cerebellar nuclei with α7 subtype more prominently expressed in 
Purkinje than the granule cells (Hill et al., 1987; Swanson et al., 1987; Wada et al., 1989; 
Caruncho et al., 1997). In granule cells, α7 expression was not detected in the soma but 
rather was found only in dendrites (Caruncho et al., 1997).  
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TABLE 2:  Autoradiographic and in situ hybridization analysis of the distribution of  
nicotinic binding sites and mRNA in rat brain (Adapted from Decker et al., 1999) 
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The expression of many nAChR subunits is regulated during developmental stages. For 
example, α4, α3 and β4 mRNA transcript is highly expressed during postnatal days P1-P14 
and then declines to adult level (De Filippi, et al., 2001). Similarly, an α3 and β4 gene 
transcript is seen during the embryonic phase but not in P5 (Zoli et al., 1995; Winzer-
Serhan & Leslie, 1997). The β4 mRNA level also fluctuates during the postnatal period; a 
weak signal at P5; moderately high after P11 and remain consistent until adulthood. The 
expression of β2 mRNA has been reported to be consistent during development. Both α-
BTX labeling and mRNA levels were low in the cerebellar cortex during development 
(Zhang et al., 1998b). However, the level rises and peaks at P14 followed by a continued 
decline until it reaches the adult level: about ten times less than P1 (De Filippi et al., 2005). 
It was also demonstrated by electrophysiological studies that α7 subtypes are localized to 
the mossy fiber-granule cell synapse during the early developmental period (De Filipi et al., 
2001). The disparity in receptor localization, reported by different investigators, may be 
explained by variation in experimental conditions, tissue selection, choice of 
ligands/antibodies, incubation time, species or strain differences.  
Desensitization of Nicotinic Acetylcholine Receptors and its Functional 
Significance 
Nicotinic receptors display three kinetically different conformational states: 1) 
resting state that has the highest affinity for the antagonists); 2) an activated state in which  
the channels are active and remain open for a brief time period (i.e. µsec to msec) but 
retain low affinity for the ligands; 3) desensitized state in which the channels are resistant  
to opening despite high agonist affinity (pM-nM) (Fig. 3)(Galazi and Changeux, 1995). 
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FIGURE 2: Schematic models for three transient states of nicotinic acetylcholine 
receptors (Balfour et al., 2000). 
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The transition among these different conformational states is regulated by triggering PKA 
and/or PKC-dependent  phosphorylation of nAChR. Both PKC and Ca2+ seem to regulate 
recovery from the desensitization phase as either replacement of external Ca2+ with Ba2+ 
or inhibition of PKC delayed recovery from nicotine-induced desensitization in Xenopus 
laevis oocytes (Fenster et al., 1999). There is also evidence that inhibition of tyrosine 
kinase increases the expression of and related response by the α7 subtype (Cho et al., 
2005). 
Various nAChR ligands exhibit selective affinity to a particular receptor state and 
can stabilize the receptor conformation in that particular state (e.g. the agonists will 
stabilize the open state from which receptors can transform into desensitized state), 
whereas antagonists can stabilize the closed state. However, long exposure to the agonist 
can transition the receptor into a state of permanent inactivation (Karlin, 1993; McGehee 
and Role, 1995). Desensitization of nAChRs represents a conservatory response to 
protect against cellular damage and synaptic changes following excessive receptor 
stimulation and Ca2+ build up. The rate, extent and duration of desensitization varies with 
agonists, exposure time, and receptor subtype involved (i.e. desensitization is faster for the  
α7 subtype than α3β2 and α2β2) while the α4β2 desensitizes more slowly than the mentioned 
subtypes (Alkondon and Albuquerque, 1993; Vibat et al., 1995). Overall, the most 
predominant α4β2/α7 subtypes exhibit the highest sensitivity to agonist-induced 
desensitization and upregulation (Hsu et al., 1996). The stoichiometric subtype  
composition of nAChRs is also a factor for differential rates of receptor desensitization and 
upregulation among various nAChR subtypes. By far, 2α4:3β2 composition has a higher  
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rate of desensitization and upregulation than 4α4:1β2 and 1α4:4β2 (Lopez-Hernandez et al., 
2004). The desensitization phenomenon has been attributed to nicotine addiction (Buisson 
and Bertrand, 2002; Gentry and Lukas, 2002), tolerance (Robinson et al., 2007) and  
nAChRs upregulation in humans (Breese et al., 1997), in rodents (Zhang et al., 1994; 
Nguyen et al., 2004) and in various cell lines (e.g. human epithelial cells [SH-EP1]), 
cultured enteric neurons, human embryonic kidney cells (HEK-293), chinese hamster 
ovary (CHO-K1) and pheochromocytoma cells (PC12) (Fenster et al., 1999; Buisson & 
Bertrand, 2002; Decker and Galligan, 2009).  
Smoking a single cigarette can elevate brain nicotine levels to 220-330nM 
(Henningfield et al., 1993), while nicotine can desensitize the α4β2 nAChR subtype at a  
concentration of 10nM as measured by decay of peak current (Paradiso et al., 2003). With 
several episodes of smoking, smokers can produce basal nicotine levels that are far higher 
than the concentration required to desensitize a significant proportion of nAChRs receptors 
in brain. This explains why smokers are tolerant to several actions of nicotine and that they 
have high nAChRs in selected brain regions such as nucleus accumbens, superior 
colliculus and hippocampus (Breese et al., 1997; Nashmi et al., 2007). Prolonged 
exposure to nicotine may inactivate α4/α7 subtype nAChRs rather than produce 
desensitization them which may account for the significant increase in density of these 
subtypes in a smoker’s brain (Peng et al., 1994; Olale et al., 1997). 
Long-term nicotine exposure upregulates both α4β2 and α7 binding sites in a variety 
of subjects like rodents (Marks et al., 1992; Nguyen et al., 2004), human (postmortem) 
brain (Breese et al., 1997)  and in vitro cells including, HEK 293, MIO, oocytes 
(Gopalakrishnan et al., 1996; Eilers et al., 1997; Molinari et al., 1998). Other agonists 
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(epbatidine, anabaseine, 1,1-dimethy 4-phenylpiperazinium) also produce an increase in 
α4β2 and α7 binding sites (Eilers et al., 1997). Interestingly, upregulation can only be 
triggered by ligand interaction with cell surface receptors as tetramethylammonium, a 
membrane-impermeant ligand that potently increases receptor number similar to nicotine 
while [3H]-epibatidine did not upregulate cell surface receptors as its binding sites lie 
intracellularly. On the other hand, the response of antagonists has been somewhat 
controversial since DHβE, methyllycaconitine, tubocurarine, hexamethonium did not alter 
receptor expression when tested in M10 cells  and SH-SY5Y neuroblastoma cells (Eilers et 
al., 1997; Riganti et al., 2005) while a relatively new antagonist, CC4, enhances both [3H]-
epibatidine or 121I-α-bungarotoxin binding sites on SH-SY5Y (Riganti et al., 2005). 
Epibatidine, a partial agonist at α4β2 subtype containing receptors upregulates the 
receptors at sub-effective concentrations without activating the receptors (Buisson et al., 
2002). 
Given the fact that a long-term increase in nicotine exposure is accompanied by two 
related phenomena of desensitization and upregulation, it was proposed that 
desensitization may provide a trigger for receptor upregulation (Mudo et al., 2007). 
However, Kishi and Steinbach (2006) clearly demonstrated that these two effects are 
distinct phenomena as mutation of amino acid residues in nAChRs  that were required for 
desensitization did not affect receptor upregulation while  mutation of the amino acids in 
the binding site prevented receptor upregulation. In addition, the concentration requirement 
for receptor desensitization varied greatly from that necessary for receptor upregulation. 
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Nicotinic Acetylcholine Receptors and Cellular Changes 
The nAChRs are mainly associated with the conductance of fast synaptic 
transmission. Low concentrations of nicotine (nM) can adequately alter the 
electrophysiological environment of neurons by promoting the cationic (Na+, K+) influx and 
burst opening of the voltage-gated ion channels. During this initial depolarization phase, 
Ca2+ influx is paramount in amplifying the initial signal by maintaining a continual supply of 
Ca2+ from extracellular and intracellular storage sites. The sustained Ca2+ signal is 
implicated in neurotransmitter release (McGehee & Role, 1995; MacDermott et al., 1999), 
and long-term adaptive changes (Dajas-Bailador et al., 2002; Dickinson et al., 2007). In 
this context, synaptic plasticity including, long-term potentiation (LTP) is paramount in 
neuronal functions such as learning, memory and addiction (McKay et al., 2007).  The 
cellular signaling molecules involved in the cognitive function includes, the cAMP response 
element binding protein (CREB) and ERK/MAPK. Other downstream cellular events that 
account for nicotine’s action and are relevant to nicotine receptor activation include, 
modulation of cGMP-NO signaling, and PKC activity (Dajas-Bailador et al., 2002). After 
chronic treatment, nicotine upregulates the mRNA transcripts of tyrosine hydroxylase (TH) 
in in vivo as well as in vitro chromaffin cells. The induction of TH mRNA is a consequence 
of sequential events that involve sustained high Ca2+ levels and activation of ERK/MAPK 
(Haycock, 1993). Chronic nicotine exposure also induces many other immediate early 
genes (e.g. cfos, c-Jun), transcription factors, protein processing factors, RNA binding and 
plasma binding proteins (Konu et al., 2001; Hu et al., 2002; Ho et al., 2004). Since 
glutamate has been regarded a major neurochemical mediator for nicotine’s action, a 
detailed review of the nicotine-glutamate system is provided in the following section. 
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Functional Relationship between Nicotine, Glutamate and Nitric Oxide 
There is sufficient evidence in the literature to support the idea that nicotine 
modulates the glutamatergic system. Nicotine increases glutamate release in rat nucleus 
accumbens after acute as well as chronic treatment (Lallemand et al., 2006). The α7 
nAChR subtype appears to exert a more modulatory influence on nicotine-glutamate 
related functions (e.g. LTP, transmitter release) than any other nAChR subtype as was 
shown in a study where nicotine and a selective α7 agonist, choline; augmented 4-
aminopyridine evoked glutamate release in rat prefrontal cortex nerve terminals through 
Ca2+-calmodulin pathways (Girod et al., 2000; Reno et al., 2004; McKay et al., 2007). 
However, in frontal cortex, the α4β2 subtype regulates the release of the excitatory 
transmitter [3H]-D-aspartate (Rousseau et al., 2005). In vitro data has also shown that 
nicotine enhanced the excitatory current at postsynaptic NMDA receptors in brain slices 
containing the amygdala (Kenny et al., 2009). Another evidence of cross-talk between 
nicotine and the glutamate system  comes from the evidence that  intra-NTS microinjection 
of nicotine elevates norepinephrine levels in PVN and AMYG  and  that this response can 
be reduced by pretreatment with the NMDA receptor antagonist (DL-2-amino-5-
phosphonopentanoic acid) but not the AMPA receptor antagonist, 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX) (Zhao et al., 2007). Nicotine-induced dopamine release 
in nucleus accumbens was markedly attenuated by NMDA and NOS inhibitors, MK-801 
and L-NNA (N-nitro-L-arginine) (Hong et al., 2006).   
 The glutamate system may also play an important role in addiction to nicotine since 
the NMDA receptor antagonist, LY 235959, reduced nicotine self-administration without 
interfering with normal food intake (Kenny et al., 2009). Also, nicotine’s effect on cognition 
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depends upon glutamate-NO signaling because the NMDA antagonist, MK-801 and nNOS 
knockout mice display significant impairment in learning and memory performances.  
(Levin et al., 1998; Wultsch et al., 2007). 
Nicotine-induced glutamate release leads to downstream activation of NO-cGMP 
signaling in several brain regions such as the cortex, hippocampus and cerebellum 
through an NMDA-receptor mediated mechanism since MK-801 and nitric oxide synthase 
(NOS) inhibitors abolish nicotine-induced NO release (Damaj et al., 1999; Pogun et al., 
2000). Nicotinic receptor activation also facilitates cationic (Na+, K+, Ca2+) influx leading to 
elevated intracellular Ca2+ levels which when combined with calmodulin stimulates NOS to 
liberate NO (Ma et al., 2008).  Nitric oxide is a biochemical molecule synthesized by NOS 
from the precursor, l-citrulline (Fig. 3) (Stuehr & Griffith, 1992; Morris, 2005). Nitric oxide 
synthase can also serve as an important neurochemical target site whereupon nicotine-
glutamate alters neuronal function (Cooper and Magwere, 2008; Ward et al., 2008).   
Nicotine exposure has also been shown to upregulate NMDA receptors in the 
amygdala and the VTA (Kenny et al., 2009). We have also demonstrated that 
intracerebellar microinfusion of nicotine attenuates ethanol ataxia in CD-1 mice through 
glutamatergic signaling downstream of nAChR activation since intracerebellar 
microinfusion of NMDA or  AMPA exacerbated while MK-801 and NBQX,  selective 
receptor antagonists at NMDA and AMPA receptors, respectively diminished the 
attenuating  action of nicotine on ethanol ataxia (Al-Rejaie and Dar, 2006a). Since 
NO/cGMP pathway is triggered subsequently to NMDA receptor activation, it is tempting to 
speculate that NO signaling may play a role in the mediation of nicotine’s effects. 
Additionally, it was found that pretreatment with SNP (sodium nitroprusside, a NO donor)  
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FIGURE 3:   Biochemical synthesis of nitric oxide from precursor L-arginine (Ghalayini et 
al.,   2004). 
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and isoliquiritigenin, a guanylyl cyclase activator also markedly elevated nicotine-induced 
attenuation of ethanol ataxia. On the other hand, pretreatment with SMT (an inhibitor of 
iNOS) and ODQ (an inhibitor of GC), diminished the nicotine-induced antagonism of 
ethanol ataxia (Al-Rejaie and Dar, 200a). Repeated intracerebellar nicotine treatment 
resulted in reversible cross-tolerance between nicotine and  ethanol ataxia (Al-  
Rejaie and Dar, 2006b, c). Again cerebellar NO production downstream of nAChRs 
contributed to the development of cross-tolerance (Al-Rejaie and Dar, 2006b, c).  
Outside the CNS, NO also mediates several functions of nicotine (Ayajiki et al., 
1997; Zhang et al., 1998a). In the vascular system, nicotine-induced relaxation occurs 
through NO release (Ayajiki et al., 1997). Nicotine generates NO from NANC nerves in 
gastrointestinal smooth muscles to relax the sphincter of Oddi (Tanobe et al., 1995). 
Guanylyl cyclase is a major cellular target for NO, which regulates basal extracellular 
levels of cGMP in several brain regions including the cerebellum (Laitinen et al., 1994). It 
has been shown that NOS inhibition by N-nitro-L-arginine methyl ester (L-NAME) reduced 
cGMP production by 74% in the cerebellum whilst NO donor, SNP, augmented cGMP 
levels by 90-fold (Laitinen et al., 1994). According to another study hippocampal 
extracellular cGMP was measured following systemic nicotine in conscious mice. The 
cGMP levels were raised after nicotine treatment and declined after localized injection of 
NOS inhibitor, N(G)-nitro-L-arginine (L-NOARG) and GC inhibitor, 1H-[1,2,4] oxadiazolo 
[4,3-A] quinoxalin-1-one ( ODQ) (Fedele et al., 1998).  
Pharmacology of Nicotine 
Nicotine is one of the most highly addictive substances known to mankind. The 
pleasurable effects of nicotine appear in the form of cognitive enhancement (learning, 
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memory, and judgment), enhanced alertness, visual attention (Jones et al., 1992), 
increased motor skills, anxiolytic actions, locomotor modulation and antinociception 
(Hindmarch et al., 1990; Jones et al., 1992). The self-rewarding effects of nicotine are due 
to DA release from the nucleus accumbens in the mesolimbic system (Clarke, 1990; 
Balfour et al., 1998) as shown in numerous in vivo and in vitro studies (Tizabi et al., 2002; 
Singer et al., 2004; Rodvelt et al., 2006), while nAChRs antagonists could abolish nicotine-
induced DA release and systemic nicotine self-administration (Neugebauer et al., 2006; 
Dwoskin et al., 2008). 
Nicotine’s effects on cognition improvement are very well established. More 
significant effects of nicotine or related nicotinic receptor agonists are observed on 
working memory than reference memory (Levin, 2002; Levin and Simon, 1998). 
Conversely, the nicotinic receptor antagonist, mecamylamine, not only prevents the 
nicotine-induced improvement in memory but also disrupts working memory 
performances (Levin and Simon, 1998). These data clearly delineate the essential 
involvement of nAChR system in regulation of memory function. Anatomical localization 
of α4β2 and α7 subtypes in memory processing areas and the fact that selective 
antagonists at these subtypes, DHβE and methyllycaconitine impair working memory 
functions indicate that both subtypes actively participate in maintaining normal memory 
functions (Addy et al., 2003). 
Nicotine has a profound impact on regulating the release of a variety of 
neurotransmitters including, norepinephrine, dopamine, 5HT, acetylcholine, glutamate, 
GABA (McGehee and Role, 1995; Picciotto et al., 1998; MacDermott et al., 1999), 
CGRP, substance P (Sastry, 1995) and growth factors such as BDNFs or FGFs which 
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play a neuroprotective role mostly through presynaptic or preterminal nAChRs in the 
CNS (French et al. 1999). Conversely, exogenously applied nAChRs antagonists can 
diminish neurotransmitter release. 
Unlike some recreational drugs like alcohol, heroin, cocaine and marijuana, nicotine 
does not have neurotoxic actions, rather it exhibits neuroprotective functions by enhancing 
the expression of neurotropic factors and nerve growth factor receptors as well by 
increasing the release of growth factors in several brain areas such as the cerebral cortex, 
hippocampus, striatum and midbrain (Belluardo et al., 2000) as well as in chromaffin cells 
in culture (Stachowiak et al., 1994). In hippocampal slices, nicotine protects against acute 
NMDA-induced neurotoxicity through the phosphatidylinositol 3-kinase and ERK/MAPK 
pathways (Ferchmin et al., 2003). The neuroprotective actions of nAChRs form the basis 
for therapeutic prospects for nAChRs agonists in the treatment of neurodegenerative 
diseases (i.e. Alzheimer’s and dementia). The most notable underlying mechanism for 
antineurotoxic actions is Janus kinases 2, PI3K phosphorylation of Akt (PKB) and 
upregulation of the anti-apoptotic marker Bcl-2 (Ferchmin et al., 2003; Mai et al., 2003) 
while prevention of glutamate toxicity involves the ERK/MAPKinases (Ferchmin et al., 
2003). Chronic exposure to nicotine or its related agonists desensitize nAChRs, which also 
participate in providing neuroprotection by shutting off excessive nAChR dependent 
intracellular Ca2+ influx that evokes neurodegenerative processes (Dani, 2001). 
Role of α4β2 subtypes in Nicotine Action 
Among the diverse variety of nAChRs subtypes, α4β2 has received the most 
attention due to its predominant distribution and its important role in mediating wide range 
of nicotine actions (Damaj et al., 1995a; Picciotto et al., 1998; Marubio et al., 1999; Perry, 
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et al., 2002; Wǜllner et al., 2008). For example, the α4β2 subtype is involved in nicotine-
induced analgesia, dopamine release, hyperthermia and locomotor stimulation (Damaj et 
al., 1995a; Cohen et al., 2003). Within α4β2, it is the β2 subunit of nAChRs which 
participates in nicotine’s actions such as analgesia, enhanced nicotine craving and 
cognition (Picciotto et al., 1998; Marubio et al., 1999). Studies in transgenic mice have 
shown that deletion of the β2 subunit abolishes nicotine’s self-administrative behavior, 
indicating the potential role of the β2 subunit in the addictive properties of nicotine (Piccioto 
et al. 1998). 
The nAChR α4β2  subtype is known to mediate the cognitive enhancing effects of 
nicotine. The selective α4β2 agonist SIB-1508Y and the nonselective α4β2 agonist, 
epibatidine demonstrate improved  performance in learning and memory related tasks in 
various animal models (Vernier et a., 1999) while the α4β2 selective antagonist, DHβE 
(30nmol), produces memory deficits in mice demonstrating  the role of the β2 containing 
subtype in cognition (Curzon et al., 1996).  Additional support for this idea was provided by 
β2 knockout mice that were devoid of any nicotine –evoked memory improvement 
(Picciotto et al., 1998).  
Nicotinic receptors also promotes the release of neurotransmitters including, 
acetylcholine, GABA, dopamine, glutamate as well as growth factor release through α4β2 
receptor subtype activation and thereby imparts neuroprotective effects (Beani et al., 1985; 
McGehee and Role, 1995; Pontieri et al., 1996; Marshall et al., 1997; Kihara et al., 1998) 
since pretreatment with DHβE blocks this neuroprotective action of nicotine (Kihara et al., 
1998). Though α7 containing receptors are regarded equally important in this regard. We 
have shown that nicotine-induced  attenuation of ethanol ataxia is primarily mediated by 
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cerebellar α4β2 in mice based on the following observations: 1) the α4β2 selective drug, (E)-
N-Methyl-4-(3-pyridinyl)-3-buten-1-amine (RJR-2403) reverts ethanol-induced ataxia in a 
dose dependent manner; 2) the α4β2-selective  antagonist, dihydro-β-erythroidine 
hydrobromide (DHβE), virtually abolished nicotine- or RJR-2403-induced attenuation of 
ethanol ataxia and; 3) α4 antisense treatment abolished RJR-2403’s effect on ethanol 
ataxia (Taslim et al., 2008). 
Role of α7 subtypes in Nicotine’s Action 
Given the highly dense population of  α7 receptors in the hippocampus; an area 
recognized for processing learning and memory, the α7 subtype remains the primary 
subtype implicated in cognitive functions. While it has been established that both α4β2 and  
α7 signaling regulate cognitive functions and that their deficit impaired learning and 
memory acquisition (Addy et al., 2003; Nott and Levin, 2006), it is α7 activation that is 
essential for both reference as well as working memory, in contrast to α4β2 which 
participates in working memory only (Chan et al., 2007). Besides, a deficit of nAChRs, in 
particularly the α7 population in hippocampus (Nott and Levin, 2006), amygdala and frontal 
cortex (Addy et al., 2003), is correlated with cognitive impairment seen in Alzheimer  and 
schizophrenic patients. 
The second major role of α7 subtype is to facilitate acetylcholine and glutamate 
release that was prevented by α7 receptor antagonist, α-bungarotoxin and α7 antisense 
oligo targeted to α7 subunit (McGehee and Role, 1995; Girod et al., 2000). On the other 
hand, postsynaptically, α7 subtypes are co-localized with GABAA receptors on rodent 
hippocampal interneurons and chick ciliary ganglion where their stimulation dampens 
GABA current. Thus, it appears that α7 signaling promotes excitatory transmission by 
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releasing glutamate and acetylcholine and by suppressing GABA release. Another 
intriguing role of α7 subtype has been mentioned in relation with its involvement in 
cannabinoid abuse (Picciotto, 2003). Both α4β2 (Picciotto, 2003; Dani and Bertrand, 2007) 
and α7 (Rassoulpour et al., 2005; Dani and Bertrand, 2007) subtypes are located on VTA 
(Dani et al., 2001), where they regulate dopamine release and mediate rewarding effects 
of nicotine. However, only the α7 subtype antagonist, methylylcaconitine when given 
systemically antagonized THC-induced self-discriminative effects and dopamine release 
and CB1 agonist, WIN 55, 212-[R] induced self-administration (Solinas et al., 2007). The 
α7 subtype is also expressed in early developmental stages and is essential in neuronal 
growth (Levin et al., 1999).  A brief summary of functional role of other nAChRs is provided 
in Table 3.  
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TABLE 3:  Summary of the functional role of nAChRs 
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Ethanol: a Social Drink or a Drug of Abuse 
Ethanol is among the oldest and most widely consumed substances of intoxication. 
The history of ethanol abuse dates back to Paleolithic age, about 8000 B.C. Unlike 
nicotine, no specific target site is attributed to ethanol’s action. Yet, the broad spectrum of 
ethanol’s action owes to its dynamic nature to interact and modulate a multitude of 
molecular and cellular targets including, GABAA, NMDA, nAChRs, 5HT receptors (Harris, 
1999), adenosine receptors (Dar et al., 1983; 1990) and PKC/PKA etc (Zhang et al., 2005; 
Newton and Messing, 2006). Ethanol’s actions on the CNS are generally well correlated 
with blood alcohol concentration and are dependent on the site of action. The action of 
ethanol can range from anxiolytic, relaxation, sedation, impaired cognition, slurred speech 
and disinhibitory behavior at moderately low doses to respiratory depression, coma, and 
death at high doses. A hallmark of ethanol’s intoxication is profound ataxia which is known 
to be produced by the modulation of excitatory-inhibitory neuronal activity by ethanol in 
cerebellum. It is therefore not surprising that ethanol drinking is responsible for a 
significant number of traffic accident-related fatalities (Caputo et al., 2007). Individuals 
exhibiting low sensitivity to motor impairing action of ethanol are more likely to develop 
alcoholism (Schuckit et al., 1994). Therefore, understanding the mechanism of action of 
ethanol in the cerebellum is an area of continuing investigation. 
Suggested Signaling Targets for Ethanol 
Owing to its high lipid solubility and small molecular size, ethanol traverses virtually 
every cell in the body and interacts with a myriad of targets to execute its action. Ethanol 
does not have a specific target or receptor site to act on and render its effects. Hence, 
ethanol utilizes a host of sites: potential targets of other endogenous or exogenous ligands 
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to deliver its function. Ethanol is considered a heterotropic ligand which binds a distinct site 
on the receptor spared by the specific ligand for that receptor (Li et al., 1998; Harris et al., 
1999). Given below is a brief overview of cellular/molecular entities that are targeted by 
ethanol. Ligand gated ion channels are integral target sites that respond to ethanol at 
concentrations ranging from 30-100 mM. Among the most notable ligand gated ion 
channels modulated by ethanol are GABAA, NMDA and  nAChRs. 
Ethanol and GABAergic System 
Modulation of the GABAergic system is a major mechanism uderlying several 
behavioral actions of acute and chronic ethanol exposure. An increase in ethanol-induced 
GABAergic neurotransmission is due to elevation of endogenous GABAergic neuroactive 
steroids, presynaptic release of GABA, and dephosphorylation of GABAA receptors leading 
to high GABA sensitivity. Several behavioral actions of ethanol involve direct or indirect 
potentiation of GABAA receptor functions. For example, the selective GABAA antagonist, 
RY023, interferes with ethanol’s rewarding, sedative and motor impairing actions and α5 
and δ subunit containing GABAA receptor knockout mice exhibit reduced ethanol 
consumption (Cook et al., 2005). We have also shown that intra-striatal microinfusion of 
the partial inverse agonist of the central benzodiazepine receptor, Ro 15-4513, significantly 
attenuated ethanol ataxia by binding with high affinity to δ-subunit of GABAA  receptors 
(Meng and Dar, 1996). 
Acute ethanol administration has been shown to increase the synthesis, expression 
and translocation of PKCβ, PKCγ and PKCε isoforms (Kumar et al., 2006).  Indirect 
activation of GABAA receptors by ethanol occurs through PKC and PKA mediated 
phosphorylation of the receptor protein (McDonald and Moss, 1997; Brandon et al., 2000). 
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As has been demonstrated in several studies the genetic deletion or knockout of some 
isoforms of PKC disrupt ethanol’s effects. For example, PKCδ knockout mice are 
insensitive to ethanol’s ataxia and PKCγ knockout mice showed less anxiolytic effects of 
ethanol (Bowers et al., 2001; Choi et al., 2008).  Chronically, ethanol elicits GABAA 
receptor internalization, reduction in sensitivity that underlie ethanol related tolerance, 
dependence and withdrawal hyperexcitability (Roca et al., 1990; Tehrani and Barnes, 
1997). Besides its main action on the GABAA receptor, ethanol also augments baclofen-
induced IPSPs at GABAB receptor subtypes (Federici et al., 2009). 
Ethanol and Glutamate Receptors 
Generally, ethanol inhibits all ionotropic glutamate receptors, though the effect and 
degree of inhibition varies with the kinetic state of the receptors in question. In the case of 
AMPA receptors, ethanol induces an increased desensitization rate (Moykkynen et al., 
2003) and, for NMDA, a decreased burst frequency and intra-burst open channel time by 
ethanol (Wright et al., 1996) that leads to channel inhibition. Acute as well as chronic 
ethanol alters the function of NMDA receptors by inhibiting Ca2+ influx through the NMDA 
receptor-coupled ion channel. Chronic ethanol exposure, in contrast, results in an 
upregulation of the NMDA receptor/ionophore complex (Iorio et al., 1992; Snell et al., 
1993). Acute ethanol also increases extraneuronal adenosine levels which in turn inhibits 
glutamate release (Clark and Dar, 1989). Overall, ethanol acts as a functional antagonist 
at the glutamate receptor and could block the excitatory transmission of glutamate at the 
postysynaptic receptor level. 
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Ethanol’s Modulation of Adenosine System 
The adenosinergic modulation of some of central effects of ethanol have been 
documented in several studies (Dar, 1990; Nagy et al., 1991; Meng and Dar, 1996). 
Previous work in this laboratory demonstrated that the brain adenosine system modulates 
ethanol ataxia, primarily via A1 receptors in three key motor areas i.e. cerebellum, striatum 
and motor cortex (Dar, 1990; Barwick and Dar, 1998). Evidence came from the 
observation that direct intra-striatal and cerebellar microinfusion of the A1-selective 
agonist, N6-cyclohexyladenosine (CHA), dose-dependently accentuated ethanol ataxia. 
Furthermore, an A1-selective antagonist but not the A2-selective antagonist, DPCPX not 
only antagonized ethanol ataxia but also reduced the accentuation produced by CHA, 
suggesting a role for tonic adenosinergic modulation of ethanol ataxia. The study revealed 
the involvement of the pertussius toxin-sensitive Gi/Go protein and cAMP as key signaling 
agents in ethanol ataxia since intra-striatal pretreatment with pertussius-toxin markedly 
antagonized the accentuation of ethanol ataxia by CHA probably by catalyzing the 
ribosylation of the α-subunit of Gi/Go. As a result there was activation of adenylyl cyclase 
and an increase in cAMP that overcame ethanol ataxia. This was further confirmed in 
studies where intra-striatal or cerebellar microinfusion of cAMP or its analog, cpt-cAMP, 
markedly antagonized ethanol ataxia (Dar, 1997). Conversely, ethanol directly increased 
the ADP ribosylation of Gi/Go protein indicating that an increase in Gi/Go protein activity 
results in inhibition of adenylyl cyclase and dimunition of cAMP levels leading to ataxia 
(Dar and Meng, 2004).            
 
 
40 
 
Ethanol and Voltage gated ion channels 
Voltage gated Na+/K+ channels respond to ethanol at concentrations less than 
100mM.  As for K+ channels, the G-protein coupled inward rectifying K+ channel (GIRK), 
the large conductance Ca-activated K+  channels (BK) and shaw 2 voltage gated channels 
(Kv3) (Dopico et al., 1998; Kobayashi et al., 1999; Lewohl et al., 1999) are primarily 
modulated by ethanol. Ethanol-induced modulation of the BK channels are activated at 
intracellular Ca2+ less than 10µM and are inhibited at intracellular Ca2+ more than 10µM. 
Ethanol depresses Na+-induced action potential generation by binding preferentially to 
nAChRs channel in the inactivated state rather than in the open state (Xiao et al., 2008). 
Besides, voltage gated Ca2+ channels can also serve as a target site for ethanol action. 
Pretreatment with non-selective Ca2+ channel inhibitor, NP 078585, can attenuate 
rewarding/reinforcing properties of ethanol (Newton et al., 2006).  
Ethanol and Enzyme Targets 
Ethanol modulates numerous kinases, which in turn regulate and alter other cellular 
proteins or behavioral responses. By inhibiting adenosine uptake, ethanol augments 
extracellular adenosine levels, which can excite A2A receptors leading to cAMP production 
and PKA activation. Once activated, PKA can trigger various cellular changes such as 
modulation of ion channel activity (Melis et al., 2002). Ethanol-induced phosphorylation of 
PKA/PKC and tyrosine kinases (i.e. Src and Fyn) are key regulators for the activity of 
ligand-gated ion channels in particular, GABAA and NMDA-coupled channels (Wafford et 
al., 1991; Anders et al., 1999; Alvestad et al., 2003). Additionally, ERK, a member of the 
mitogen-activated protein kinase family also constitutes an important target for ethanol 
reinforcing action as inhibition of this kinase can greatly augment ethanol self -
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administration (Faccidomo et a.l, 2009). With one single injection, ethanol can trigger 
CREB phosphorylation, which is implicated in long-lasting synaptic plasticity (Camarini and 
Hodge, 2004).  Furthermore, ethanol-induced release of GABA at Golgi cell-Purkinje cell 
synapse is regulated by adenylyl cyclase-PKA signaling since AC and PKA antagonists 
can blunt GABA release (Kelm et al., 2008). 
Ethanol and Nitric Oxide 
Endogenous NO is an inorganic, highly diffusible, lipid soluble gas with a biological 
half-life of only a few seconds. Nitric oxide is synthesized in mammalian systems by the 
action of one of  three NOS isoforms: inducible (iNOS), endothelial (eNOS) and neuronal 
(nNOS) which catalyze the conversion of l-arginine to NO and l-citrulline using several and 
cofactors (i.e. FMN, FAD, NADPH, BH4) (Stuehr and Griffith, 1992). Nitric oxide is a highly 
reactive and unstable chemical and is immediately degraded to nitrite (NO2
-) and nitrate 
(NO3
-) (Knowle & Moncada, 1994). Nitric oxide can also react with superoxide (O2
-) to form 
a highly toxic oxidizing reagent, peroxynitrite (Beckman et al., 1990). Thus, excessive NO 
production, albeit contributed largely by iNOS imparts a cytotoxic action (Calabrese et al. 
2007).  Virtually all neurons express the housekeeping isoform nNOS and possess the 
mRNA for iNOS which is translated under pathological conditions (Snyder, 1994). In the 
CNS, NO serves as a biological mediator of neurotransmitter release, gene expression, 
cell survival, blood flow, cognition, and immunomodulation.  
The effect of ethanol on NOS enzymes and subsequent NO release varies 
depending upon the site, dose and duration of ethanol exposure. Consequently, the 
existing literature contains data showing increases (Chandler et al., 1997), decreases 
(Zima et al., 1998) and no alteration (Ikeda et al., 1999) in NOS activity following acute or 
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chronic ethanol treatment. Despite the variability of the action of ethanol on the NO 
system, NO appears to mediate several effects of ethanol. Nitric oxide plays a key role in 
ethanol preference as L-NO arginine, a potent inhibitor of NOS, reduces ethanol self-
administration without altering normal feeding behavior (Calapai et al., 1996). Another 
study shows that pretreatment with 7-nitroindazole, a selective nNOS inhibitor, blocked 
ethanol-induced locomotor sensitization responses and condition placed preference in 
mice (Itzhark and Martin, 2002). 
NO has also been implicated in the production of tolerance to ethanol-induced 
motor incoordination as inhibitors of cGMP, such as LY83583 and ODQ, prevented the 
development of tolerance to ethanol’s action while the cGMP analogue, 8-bromo-cGMP, 
and the NO donors, SNAP or sodium nitroprusside, increased ethanol tolerance (Wazlawik 
and Morato, 2003). Similarly, nNOS knockout rats were less sens itive to ethanol’s sedative 
(Spanagel et al., 2002), hyperlocomotion action (Itzhak and Anderson, 2008) and did not 
develop rapid tolerance to ethanol- induced hypothermia versus wild type animals 
(Spanagel et al., 2002). 
Nitric oxide is also critical in the ethanol withdrawal response. Inhibition of NOS 
ameliorates some symptoms of ethanol withdrawal as shown in a study where 
pretreatment with the nNOS inhibitors,  N-nitro-L-arginine methyl ester  (L-NAME) and 7-
nitroindazole (7-NI), significantly controlled ethanol withdrawal signs (hyperlocomotion, 
audiogenic seizures) while l-arginine administration potentiated ethanol’s withdrawal 
responses ((Uzbay & Erden, 2003). Nitric oxide protects the neuronal population in the 
hippocampus, the dentate gyrus and the neocortex against ethanol-induced toxicity as 
nNOS knockout (-/-) mice suffer more alcohol-induced toxicity than wild type mice 
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(Bonthius et al., 2006).  It has been shown that chronic ethanol exposure to maternal rats 
reduced NOS expression in the hippocampus of young offspring thus providing a clue to 
the underlying ethanol-related developmental retardation and abnormalities (Jang et al., 
2005).  Besides its action on nNOS, ethanol pretreatment also inhibits cytokine-induced 
iNOS activity in immortalized astrocytes (Wang and Sun, 2001). Ethanol can also markedly 
inhibit highly expressed NOS in cerebellar granule and basket cells (Fataccioli et al., 
1997). 
Nicotine-Ethanol Interaction 
Nicotine and alcohol are the two most damaging and addictive substances in our 
society that are very frequently used by the same individuals. It is generally true that a 
significant proportion of alcoholics smoke and are also nicotine-dependent (Littleton et al., 
2007).  It is equally true that for people who are dependent upon alcohol, tobacco is one of 
the most commonly co-abused substances (Ceballos 2006).  The concurrent use of 
nicotine and alcohol in humans has long been documented by several epidemiological 
studies (Hays et al., 1999; Anthony et al. 2000; Meyerhoff et al., 2006).  Nearly 80-90% of 
alcoholics smoke regularly (Pomerleau et al., 1997; Romberger and Grant, 2004) and 
alcoholism is approximately 10 times more prevalent in smokers than nonsmokers 
(DiFranza and Guerrera, 1990).  
Generally, consensus exists among researchers that the primary cause of this co-
addiction is the fact that nicotine and ethanol synergistically release more dopamine in the 
reward pathway than either drug alone (Soderpalm et al., 2000; Narahashi et al., 2001). It 
has also been suggested that there are other sites wherein these drugs modulate each 
other’s physiological effects that may also contribute to co-addiction. However, the precise 
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mechanism(s) of co-abuse is/are not known probably because of the complex functional 
relationship between the two drugs of abuse. Within the CNS both drugs modulate the 
action of each other in a bi-directional manner. For example when ethanol acts as a co-
agonist it augments nicotine’s locomotor stimulatory, rearing (Lapin et al., 1995; Watson 
and Little, 1999) and rewarding activity (Korkosz et al., 2006a).  Conversely, ethanol also 
exhibits antagonistic functional interactions with nicotine.  For example, ethanol reduces 
nicotine-induced seizures (Korkosz et al., 2006b) and improvement in cognitive functions 
(Rezvani and Levin, 2002). Chronically, ethanol abolishes the hypothermic effects of 
nicotine (Majchrzak and Dilsaver, 1992). In vitro, ethanol prevents nicotine-induced 
inhibition of Purkinje neurons as measured by extracellular single-unit recording (Yang et 
al., 1999). Similarly, nicotine also facilitates or counters ethanol related actions.  For 
example, subchronic nicotine treatment leads to increased ethanol consumption in rats 
(Larsson and Engel, 2004) and exposure of young rats to nicotine during adolescence 
results in higher ethanol consumption at adulthood (Tsui et al., 2001).  Nicotine attenuates 
the ethanol-induced increase in glucose utilization in mouse cerebellar tissue (Anwer and 
Dar, 1995). In cerebellar cortical and granule cells, nicotine decreases ethanol-induced 
caspase 3 activity and subsequent cytotoxicity (Tizabi et al., 2005).  Nicotine blocks 
ethanol-induced impairment in contextual and cued fear conditioning (Gulick and Gould, 
2008).  
Ethanol and Nicotinic Acetylcholine Receptors  
Several behavioral actions of ethanol are mediated by nAChRs. For example, 
ethanol-induced dopamine release in the reward pathway and locomotor stimulation 
require activation of nAChR as the non-selective nAChR antagonist, mecamylamine, 
45 
 
reduced both actions of ethanol (Soderpalm et al., 2000). Ethanol, acting as co-agonist at 
nAChRs, facilitates the binding of nicotine (Tonner et al., 1992), and stabilizes the open 
state of the nAChR channel (Wu et al., 1994). Chronic ethanol administration increases 
nicotine binding sites in the brain (Collins et al., 1996) but decreases binding sites in M10 
and SH-SY5Y neuroblastoma cells (Gorbounova et al., 1998). The action of ethanol’s 
action on nAChR subtypes is differential as evidenced by the observation that ethanol 
potentiates the agonist-induced current at α4β2 subtype receptors and inhibits the α7-
induced current in recombinant preparation of Xenopus Lae vis oocytes (Narahashi et al., 
1999; Zuo et al., 2002). Since α4β2  and α7 are the predominant nAChR sutype, a detailed 
account of the role of each subtype in ethanol’s action is given below.  
Role of α4β2 Subtype in Ethanol’s Action 
The role of α4β2-containing nAChRs in contributing to ethanol action is controversial. 
Some in vitro studies also support the idea that ethanol potentiates the agonist-induced 
current at α4β2, α3β2, α2β2 nAChRs in rat cortical neurons (Aistrup et al., 1999) and 
Xenopus oocytes (Covernton & Connolly, 1997). Tritto et al. (2004) have shown the 
participation of α4 subunit containing nAChRs in mediating ethanol’s increase in locomotor 
activity. Previously, we have demonstrated that intracerebellar microinfusion of nicotine 
attenuates ethanol ataxia in a dose-dependent fashion through a glutamate-nitric oxide-
cGMP signaling pathway (Dar et al., 1993; Dar et al., 1994; Al-Rejaie and Dar, 2006b, c). 
Conversely, data exist that do not support any role of  α4β2-containing nAChR subtypes in 
mediating the release of dopamine by ethanol, locomotor stimulation and rewarding effect 
also was reported (Le et al., 2000; Larsson et al., 2002; 2004). According to Larsson et al. 
(2002) selective antagonism using α4β2 receptor antagonist, DHβE, as well as by selective 
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α7 blocker, methyllycaconitine, does not diminish ethanol-induced locomotor stimulation 
and dopamine release in nucleus accumbens. Rather a negative allosteric modulator of 
nAChRs, mecamylamine, attenuates these actions of ethanol by a mechanism different 
from direct inhibition of α4β2 or α7 subtypes function (Larsson et al., 2002). 
Role of α7 Subtype in Ethanol’s Action 
Ethanol-induced dopamine release and hyperlocomotor activities are mediated 
through non-α4β2 and non-α7 containing nAChRs as selective antagonists at these 
subtypes failed to prevent these actions of ethanol (Le et al., 2000; Larsson et al., 2002; 
2004). On the other hand, varenicline, a novel α7-selective full agonist and α4β2 partial 
agonist, has proven effective in decreasing ethanol consumption in laboratory animals 
(Steensland et al., 2007). Varenicline (Chantax®) has recently been approved and is 
clinically available for smoking cessation. Varenicline also improved ethanol-induced 
impairment in contextual (Gulick and Gould, 2008) and cue associative learning 
(Steensland et al., 2007) indicating that the nAChR α7 subtype might have some 
contribution in some behavioral actions of ethanol. Moreover, α7 knockout mice exhibited 
heightened sensitivity to ethanol-induced loss of rightening reflex (LORR) and an increase 
in open-field activity (Bowers et al., 2005). These findings were supported by the 
observation that genotypic alcohol sensitive long-sleep mice have significantly reduced 
density of cerebellar α7 subtype (de Fiebre et al., 1987).  Consequently, these mice display 
greater sensitivity to the depressant effects of ethanol such as sedation and hypnosis 
(Bowers et al., 2005). Since LORR is a consequence of ethanol-mediated depression of 
cerebellar Purkinje cells, it has been proposed that cerebellar α7 subtypes tonically oppose 
ethanol-induced LORR (Bowers et al. 2005). Despite the given role of α4β2 and α7 subtype 
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in nicotine-ethanol, no study to the best of our knowledge has looked into the participation 
of these subtypes in the mediation of ethanol ataxia that results from ethanol-induced 
disruption in rhythmic firing of cerebellar neurons (Carta et al., 2004; Botta et al., 2007). 
  
 
 
CHAPTER TWO: EXPERIMENTAL PROCEDURES 
 
Animals  
Male mice (Charles River, Raleigh, NC) of CD-1 (ICR) strain, weighing 22-24 g 
and 5-6 weeks old were used in all studies reported. This inbred strain of mice at this age 
and body weight are considered adult (based on consultation with Animal Care 
Veterinarian) and have been used in the ongoing research since 1980. These mice exhibit 
a very consistent ataxic response due to ethanol. Older and heavier animals do not 
provide consistent responses in their Rotorod behavior.   Upon arrival, the animals were 
housed 8 per cage, and fed commercial pellet food and water ad libitum. The animals were 
kept in housing quarters under controlled humidity (60-80%) and temperature 22-24oC and 
maintained on a 12-h light/dark cycle, with lights on at 07:00 h.  The animals were allowed 
to acclimatize to their housing conditions at least for 24 h before survival stereotaxic 
surgery. Following implantation of the permanent guide cannulas for drug microinfusion, 
each animal was housed individually in a plastic cage.  The animals were used only once 
in the Rotorod experiment.  The use of animals in the present study was in accordance to 
the laboratory animal use protocol approved by the University’s Animal Care and Use 
Committee consistent with the NIH Guide for the Care and Use of Laboratory Animals.   
Drugs Used in the Project 
The following drugs  and concentration were used in the study: (-)-nicotine-di-L-
tartrate (5ng); α4β2-selective nAChR subtype agonist, N-methyl-4-(3-pyridinyl)-3-buten-1-
amine (RJR-2403; 31 62, 125, 500 ng); α4β2-selective nAChR subtype antagonist, dihydro-
β-erythroidine hydrobromide (DHβE; 125, 250, 500, 750 ng), α7 selective agonist, N-(3R)-
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1-Azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide (PNU-282987 2.5µg, 250 ng, 25 ng); α7 
selective antagonist, methyllycaconitine (MLA, 3, 6, 12ng). RJR-2403 and PNU-282987 
were purchased from Tocris (Ellisville, MO, USA) whereas Sigma-Aldrich (St. Louis, MO, 
USA) was the source of nicotine, DHβE and methyllycaconitine. Stock solutions of 
nicotine, RJR-2403, DHβE and methyllycaconitine were prepared in artificial cerebrospinal 
fluid (aCSF) containing in (mM): NaCl (127.65); KCl (2.55); CaCl2 (0.95); MgCl2 (0.94); 
Na2S2O5 (0.05) at pH 7.4 and PNU-282987 was dissolved in 100% dimethylsulfoxide 
(DMSO). To maintain the stability of drug solutions, aliquots of the stock drug solutions 
were prepared and stored at -70◦C while the working concentrations of drugs were either 
prepared on the day of the experiment or a day before and kept at -70◦C. Ethanol solution 
(10% v/v) was prepared from absolute ethanol, diluted with 0.9% sterile saline and was 
administered i.p. at a dose of 2g/kg (0.2ml/10g). Chloral hydrate was diluted in sterile 
water to achieve the desired dose of 450mg/kg (0.1ml/10g of body weight; i.p.). The 
ethanol dose of 2g/kg results in a blood alcohol concentration of about 185 mg/dL (~ 38 
nM) based on previous studies from this laboratory (Dar, 1988).  This dose consistently 
produces motor impairment with no loss of righting reflex and without overt sedation or 
hypnosis. It is comparable to the blood alcohol concentrations (22 to 33 nM = 100 – 150 
mg/dL) that occur following moderate social drinking in humans who experience consistent 
psychomotor impairment but no sleep or overt sedation. 
Synthesis of Oligonucleotides  
Oligonucleotides were custom-synthesized, containing a phosphorothioate 
backbone and purified by Integrated DNA Technologies, Inc. (IDT, San Diego, CA, USA). 
Sequences of α4β2 and α7 subtypes antisense and missense, obtained from the published 
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literature (Yu and Role, 1998; Bitner et al., 2000), were as follows: α4β2 antisense 5`-
(CGAATTGGCCATGGTGAAGC); missense 5`-(CAGATTGGCCATGGTGAGAC); α7 
antisense 5`-(GCATCAGCGCCCGGA)-3`; missense 5`-(GCAACAGAGCCAGGA)-3`. The 
oligos were dissolved in an appropriate volume of sterile water to provide a final 
concentration of 200nM.   
Stereotaxic Surgery for Cannula Implantation 
  Mice, under chloral hydrate (450 mg/kg, i.p.) anesthesia and Ketorolac analgesia 
(2mg/kg; s.c), were stereotaxically implanted with a permanent indwelling stainless-steel 
guide cannula for microinfusion of drugs directly into the cerebellum (Fig. 4). Anesthetized 
animals were placed in a stereotaxic apparatus (Model 900; David Kopf Instruments, 
Tujunga, CA, USA) and the guide cannula implanted according to coordinates of Slotnik 
and Leonard (1975). The coordinates for the cerebellar cannulation were: AP,-6.4 mm 
(bregma); ML, ± 0.8 mm, DV,-1.0 mm: from the skull surface. The guide cannula was 
constructed from 22-gauge stainless steel tubing, cut to a length of 10 mm and lowered to 
the desired depth through the appropriately located craniotomy holes. They were anchored 
with fast drying carboxylase-cement, Durelon® (Premier Dental Products Co., Norristown, 
PA, USA) to the cranial surface that had been scraped clean of periosteum. A minimum 
period of at least 4 days was allowed for the recovery of mice from the surgical trauma and 
the anesthesia before their use in behavioral experiments. The surgical implantation of the 
indwelling cannula was carried out under aseptic conditions. The cranial surface was 
routinely cleaned by swab sticks of povidone-iodine solution, (The Clinipad Co., Rocky Hill, 
CT, USA). The guide cannula, drill burs and surgical tools were autoclaved prior to use. 
Currently, 95% of animals successfully recover post-operatively for use in behavioral  
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FIGURE 4: Diagram of sagittal view of stainless steel guide annula surgically 
implanted into anterior lobe region of mouse cerebellum. The injection cannul protrudes 
one mm beyond the ventral tip of the guide cannula 
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experiments. To minimize possible infection, aseptic surgical techniques were followed 
consistent with the approved animal use protocol. All animals received subcutaneous (s.c.) 
3000 units of Durapen®, (VEDCO Inc, MO, USA), a combination of benzathine and 
procaine penicillin G suspension immediately after surgery. Animals also received 
injections (2mg/kg, s.c.) of an analgesic, ketorolac tromethamine (Abbot Laboratories, 
North Chicago, IL, USA) before and four hours after surgery. 
Rotorod Treadmill - motor coordination 
The degree of motor impairment was determined using a standard mouse Rotorod 
treadmill (UGO Basile, Verese Italy), calibrated for a fixed speed of 24 rpm (Dar, 1990; 
Smith and Dar, 2007). Mice were allowed to acclimatize to the treadmill by placing them on 
it 2-3 times immediately prior to the actual experiment.  It was important to test each 
mouse for its motor coordination before its use in Rotorod study in case of an inborn 
cerebellar defect. The screening test now used in our laboratory requires each animal to 
remain on the Rotorod for 180 s. Based on repeated observations for over 25 years, less 
than 3% of all mice tested fail to meet this criterion. Only successfully screened animals 
received pretreatment (aCSF/oligonucleotides/or nicotinic drugs) followed 5 min (in case of 
drugs) and 16 h (in case of oligonucleotides) by the i.p. injection of the test dose (2g/kg) of 
ethanol. The index of motor coordination was always evaluated every 15 min for 60 min 
starting immediately after ethanol administration. To avoid the influence of diurnal variation 
on the motor behavior of animals, all Rotorod experiments were conducted between 8:00 
am and noon. 
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Intracerebellar Microinfusion of Drugs  
In this dissertation research, all nicotinic drugs including, α4β2 and α7 antisense 
and missense oligonucleotides were microinfused directly into the culmen of the anterior 
lobe of the cerebellum through an injector cannula (11mm length, 30-gauge) connected via 
a polyethylene tube (Clay Adams, Parsippany, NJ, USA) to a 25 µl Hamilton microsyringe. 
The microsyringe was fitted onto a microinfusion pump (Model 22, Harvard Apparatus, 
South Natick, MA, USA), which regulated the constant infusion rate. The injector cannula 
was inserted into the guide cannula and was allowed to protrude 1 mm beyond the lower 
tip of the guide cannula. An air bubble introduced in the PE-10 tube helped track the flow 
of drug solution. Unless otherwise state, the animals received an ICB microinfusion of one 
drug followed 8-10 min later by ethanol administration (Fig.5). The Rotorod test was 
performed 15 min after the ethanol injection. In the case of two ICB drug treatments, first, 
the animals received an ICB microinfusion of the agonist, followed by the antagonist after 5 
min interval and then the Rotorod test was conducted (Fig. 5). Oligonucleotides were also 
administered under the same setting with the following protocol: 200nM, twice a day for 4 
days. Ethanol as stated above was administered i.p. throughout this project.  
Protocol for Chronic Study 
Presented in Figure 6 is a brief overview of the experimental protocol used to 
study the consequences of repeated intracerebellar microinfusion of nicotinic agonists and 
antagonists as well as the development of cross-tolerance between repeated RJR-2403  or 
PNU-282987 and acute ethanol induced ataxia. The details of the experiments are 
presented below: 
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FIGURE 5:  Schematic diagram showing the drug administration protocol in acute studies  
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Dose-Response Relationships. In order to determine if the development of tolerance to 
acute ethanol-induced ataxia following repeated RJR-2403 (31, 62,125ng) and PNU-
282987 (25ng, 250ng, 2.5µg) was dose dependent, α4β2 and α7  selective agonists were 
microinfused directly into the cerebellar cortex once daily for 7 days (RJR-2403) and for 5 
days (PNU-282987). Sixteen hours after the last RJR-2403 and PNU-282987 
intracerebellar microinfusion, the test dose of ethanol was administered as explained in 
Rotorod procedure and motor incoordination was evaluated 15-60 min post-ethanol 
injection. 
Onset of Tolerance. To determine the time when the development of cross-tolerance is 
first observed following repeated intracerebellar microinfusion, an optimum dose of RJR-
2403 and PNU-282987 was selected from dose-response data. The RJR-2403 dose of 
125ng was selected based on the dose-response experiments. This dose was routinely 
used in determining the “onset and the duration of the cross-tolerance” between RJR-2403 
and acute ethanol ataxia. Similarly, the dose of PNU-282987 selected was 250ng that was 
used in experiments to determine the “onset and duration of the cross-tolerance”. Animals 
were repeatedly treated with ICB RJR-2403 (125ng for 1, 2, 3, 5, 7 days) and PNU-282987 
(250ng for 1, 3, 5 days). Finally, 16 h after the last agonist injection, the test dose of 
ethanol was administered and ethanol ataxia was evaluated. 
Duration of Tolerance. After determination of the time for onset of development of cross 
tolerance, we sought to find out the total time for which cross-tolerance persisted. Again, 
animals were microinfused with RJR-2403 (125ng; once a day for 7 days) and PNU-
282987 (250ng; once a day for 5 days). Ethanol ataxia was evaluated starting 16 h after 
the last drug treatment and continued until the effect of the drug tapered off. 
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FIGURE 6:   Schematic diagram showing the protocol for chronic study 
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Participation of nAChR Subtypes in Tolerance Development. To confirm the 
participation of specific nAChR subtypes in the development of cross-tolerance between 
nAChR subtypes α4β2 and α7 and the acute ethanol ataxia,  mice were pretreated with 
α4β2- and α7-selective antagonists, DHβE and methyllycaconitine, respectively, followed by 
the agonist drugs RJR-2403 or PNU-282987 as before. Sixteen hours after the last 
microinfusion of RJR-2403 or PNU-282987, motor incoordination was assessed as before. 
Histology 
It was important to confirm the accuracy of guide cannula implantation as well as 
of the drug microinfusions.  Therefore, at the conclusion of each behavioral experiment, 
100 nL of Fast Green dye was microinfused into each animal through the guide cannula. 
Mice were euthanized by cervical dislocation and decapitation under light Isoflurane 
anesthesia (IsoFlo; Abbott Laboratories, North Chicago, IL, USA). The guide cannulas and 
the brains were carefully removed and the correctness of microinfusion site was verified 
by visual observation of the presence of dye in the cerebellar anterior lobe region. Only 
animals in which the cannula placement was histologically verified as correct were 
included in the data analysis. The brains were frozen at -20◦C and subsequently, 20μm 
thick coronal sections were obtained with a Tissue-Tek II cryostat (Mills Laboratories, 
Naperville, IL, USA). The sections were mounted onto a clean glass slide, allowed to air 
dry and then stained with cresyl violet. The sections were examined under light 
microscope to assess the integrity of cerebellar cortex after repeated nicotinic drugs or 
oligonucleotide treatment and to confirm the accuracy of drug microinfusion site. 
Histological photomicrographs were taken with a spot Insight Digital Camera connected to 
an Olympus Bx51 microscope at 12.5x. In the present dissertation research 100% of the 
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cannula implantation was successful.  Based on the examination of histologic 
photomicrographs of cerebellar tissues from randomly selected mice, a minimal variation 
between and within groups and treatments in the drug dispersion sites of microinfusions 
and the extent of tissue damage due to cannula implantation was observed. The 
histological data also confirmed the drug dispersion following its intracerebellar 
microinfusion remained confined to the cerebellar tissues consistent with previous studies 
(Meng and Dar, 1996). 
Immunoblot Experiment  
Preparation of Membrane Fraction.  For preparation of membrane proteins, 
oligonucleotide-treated mice were sacrificed by cervical dislocation and decapitation. 
After careful removal and transfer of brains to an ice cold glass plate surface, cerebellar 
tissues were cut out around the site of the guide cannula implantation. The cerebellar 
tissues from 5 animals were pooled to increase the amount of the available proteins in 
the tissue sample. Six volumes of ice cold Tris buffer (20 mM Tris, 2 mM EDTA, 250 mM 
sucrose) were added and the samples were homogenized using a glass Teflon 
homogenizer. Homogenates were centrifuged at 2000 x g for 5 min at 4◦C, the resultant 
supernatants were re-centrifuged at 22,000 x g for 30 min. Finally, the pellets were 
resuspended in Tris buffer, the suspension was well shaken, divided into aliquots and 
stored at -20◦C until the day of the experiment. Protein measurements were made using 
the BCA protein assay (Thermo Fisher Inc. Rockford, IL, USA). 
Western Blot Analysis. Eighty µg of membrane protein were size fractionated using 
10% SDS-PAGE, followed by transfer onto nitrocellulose at 100V for 100 mins. The 
membranes were blocked with 1x casein (Vector Laboratories, Burlingame, CA, USA) in 
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Tris-buffered saline-T [20 mM Tris, 500 mM NaCl, 0.1% Tween 20 (TBS-T), pH 7.6] for 4 
hours at room temperature followed by incubation with primary rat antibody directed 
against the α4 and the α7 subunit of nAChRs (Covance Research Products, Berkley, CA, 
USA) at 1:500 dilution with TBST-casein at 4◦C overnight.  After washing with TBST-T for 
3x5min, membranes were probed with secondary goat anti-rat horseradish peroxidase 
conjugated antibody in a 1:5000 dilution (Santa Cruz, Biotechnologies, Inc. Delware, CA, 
USA) for 2 hours at room temperature. This was followed by 3x5 min wash with TBST-T. 
Specific protein bands were visualized using the ECL western blotting detection reagent 
and the Versadoc Imaging System (Bio-Rad Laboratories, Richmond, CA, USA). The 
peak density of the bands was measured. 
Biochemical Study  
Nitric oxide Assay. Intracerebellar concentrations of highly unstable nitric oxide (NO) 
were measured indirectly by reading its reactive metabolites (i.e. nitrite and nitrate [NOx]) 
using DAN fluorimetric methods (Rao et al., 1998; Al-Rejaie & Dar, 2006a,b). 
Cerebellar Tissue Preparation. All glass and plastic wares used in the procedure were 
washed thoroughly with de-ionized water and were air dried before the experiment to 
minimize interference from the environmental NO. Following the ICB nicotinic drug 
treatment and ethanol or saline i.p. administration, mice were euthanized 15 min post-
ethanol injection, by cervical dislocation and decapitation. This time point was selected 
based on the ethanol response curve in the Rotorod results wherein ethanol ataxia 
peaked at 15 min post-injection. Brains were removed from the skull and placed on an 
ice-cold glass plate.The cerebellar tissue surrounding the guide cannula mark was 
dissected out (Fig. 7) and immediately frozen in liquid nitrogen. The frozen tissues were  
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FIGURE 7: Schematic diagram showing the area where both treated and contralateral 
cerebellar tissue was dissected  
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weighed in a tared tube and homogenized in eight volumes of Tris EDTA buffer pH 7.4 
using a Polytron tissue homogenizer (Polytron Model PT 10/35, Brinkman Instruments, 
Westbury, NY, USA). Typically, samples obtained from each animal weighed 15-30mg. 
All samples were centrifuged at 4000xg for 20 min. The crude filtrate was 
ultracentrifuged through 10,000 MW cutoff microcentrifuge filters (Microcon® YM-10, 
Amicon® Bioseparations, Millipore Co., Bedford, MA, USA) at 16,000xg for 60 min at 
4°C. The clear ultrafiltrate obtained was free of hemoglobin  and other protein 
contamination that have been reported to interfere with the assay results (Fernandez-
cancio et al., 2001). Detection of cerebellar NOx concentration was done in a 2-step 
procedure. First, the tissue nitrate was enzymatically converted to nitrite by NADPH-
dependent nitrate reductase. Second, the nitrite was allowed to react with DAN to form a 
fluorescent product, 2, 3-naphthotrazole, that was measured fluorometrically. The actual 
assay procedure involved pipetting 100 μl of the sample cocktail containing, 20 µl  of 750 
µM G-6-P, 20 µl of G-6-PDH (48 mU), 20 µl of 3 µM NADPH, 20 µl of nitrate reductase 
(30 mU), and 20 µl of ultrafiltrate sample in a  20 mM Tris-10 mM EDTA buffer, pH 7.4 
mixture into a separate well in a white 96-well flat-bottom plate (Costar; Corning 
Glassworks, Corning, NY, USA). Samples were incubated for 90 min at 25°C. At the end 
of the incubation, 100 µl of freshly prepared sodium nitrite standard  solutions (50–1000 
pmol) were transferred into separate wells. This was followed by the addition of 30 µl  of 
DAN solution (0.05 mg/ml in 0.62 N HCl) to each well and the plates were incubated in 
the dark for an additional 10 min. The reaction was stopped by adding 30 µl of 1.4 N 
NaOH. The intensity of the fluorescent signal was immediately measured using a 
fluorometer (FL600 Microplate Reader; Bio-Tek Instruments, Winooski, VT) at ex = 360 
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and em = 460. The concentration of
 NOx in each sample was calculated from a standard 
curve generated by plotting the fluorescent units with a sodium nitrite concentration in 
picomoles using KC4 software (Bio-Tek Instruments). Results are expressed in 
picomoles per milligram of fresh tissue consistent with others (Seo and Revier, 2003). 
Total NOx present in each
 sample was calculated as follows: total NOx = [NOx in sample
 
(picomoles) x total volume added (microliters)/20 µl] per milligram of tissue. 
Immunohistochemistry 
For immunohistochemistry experiments, mice were anesthetized with chloral 
hydrate. Brains were fixed by cardiac perfusion with 1xPBS followed by 4% 
paraformaldehyde. After removal, brains were  immersed in 4% paraformaldehyde 
overnight. The following morning, post-fixed brains were soaked in 20% sucrose until 
sectioning. Parasagital brain slices were obtained with a vibrating microtome. The 
selected slices were washed in 0.1% hydrogen peroxide for 30 min followed by blocking 
in 5% goat serum for 30 min. Then brain slices were probed overnight with the 
appropriate dilution of α4β2 (1:1000) or α7 (1:500) antibody. Subsequently, sections were 
washed three times with PBS followed by re-incubation with secondary antibody (1:5000) 
for 1-2 hours and again washing three times with PBS. Afterwards, sections were stained 
using a diaminobenzidine staining solution obtained as kit from Vector Laboratories 
(Burlingame, CA, USA). Immunoreactivity was examined with an Olympus BX51 
microscope equipped with Normarski DIC optics under 12.5, 100 and 600x.  
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Statistical analysis 
The Rotorod data were analyzed by analysis of variance (ANOVA) with two-way 
repeated measure in order to evaluate the effect of various drug doses and times on 
motor coordination. The drug dosage × time interaction effect was tested using the 
multivariate criterion of Wilk's lambda (λ). Significant drug × time interaction was 
evaluated using a one-way ANOVA. A Dunnett's C post hoc test was performed 
whenever significance was found on treatment and/or time. Statistical analyses were 
conducted using SPSS for Windows, version 16.0. Area under the curve (AUC) analysis 
was performed using GraphPad Prism 4.0©.  Data comparing NOx levels were analyzed 
by Student’s t-test and one-way analysis of variance (ANOVA) and Bonferroni post hoc 
analysis. A p-value < 0.05 was taken as the level of significance in all statistical tests. 
 
 
 
 
CHAPTER THREE: RESULTS 
 
Consistent with previous work in this laboratory, ethanol produced profound ataxia 
that was measured starting at 15 min intervals post-ethanol injection time until the animals 
regained their normal motor coordination. Typically, ethanol control mice were able to walk 
on Rotorod at 15 min post-ethanol evaluation for only 40 sec; 65 sec at 30 min; 125 sec at 
45 min.  The animals generally regained their normal motor coordination (Rotorod walk for 
180 sec) by 60 min post-ethanol injection.   
Acute Intracerebellar (ICB) Microinfusion of RJR-2403 and acute Ethanol Ataxia: 
Functional Interaction  
Effect of Intracerebellar Acute RJR-2403 on Ethanol Ataxia. Figure 8A demonstrates 
the dose-response relationship between the attenuating effect of various ICB doses of 
RJR-2403 on ethanol-induced ataxia. As shown in Fig. 8A, RJR-2403 markedly 
attenuated ethanol ataxia in a dose-related fashion. Significant drug treatment and time 
interaction F (9,114) = 22.54, p<0.05 was observed.  For ethanol control response ICB 
aCSF was microinfused in a group of animals instead of RJR-2403 followed by the 
administration of test dose of ethanol. All four RJR-2403 doses (31, 62, 125, 500 ng) 
produced statistically significant attenuation in ethanol ataxia compared to aCSF + 
ethanol control animals. Treatment with ICB RJR-2403 500ng caused total blockade of 
motor impairing effect of ethanol and abolished the ethanol ataxia. The reduction in 
ataxia following treatment with RJR-2403 at a dose of 125ng was 91% at 15 min 
(p<0.05) and 100% at 30, 45 and 60 min. Treatments with RJR-2403 62 ng and 31 ng 
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dose resulted in decrease in ethanol ataxia by 45% (p<0.05) and 21% (p<0.05) at 15 min 
and 83% (p<0.05) and 66% (p<0.05) at 30 min, respectively. Virtually, all animals in the 
RJR-2403 treated groups regained their normal motor coordination by 45 min with 
p<0.05 vs. ethanol controls.  Figure 8B shows the area under the curve (AUC) analysis 
of the same treatment groups from Fig.8A. The AUC inversely correlates with the degree 
of ataxia observed after ICB drug treatment with RJR-2403 or aCSF. As the the dose of 
RJR-2403 increases from 31 to 500 ng, the AUC correspondingly decreases in a dose-
related manner consistent with decreased cerebellar ethanol-induced ataxia. Thus, 
aCSF + ethanol (i.e. ethanol control group) exhibited the largest AUC and RJR-2403 500 
ng + ethanol treatment the least. The specific drug treatments in Fig. 8A are indicated 
above the appropriate bars. There were no overt signs of CNS excitation due to any of 
the RJR-2403 doses selected in this study. When the highest dose of RJR-2403 (500 ng) 
was microinfused followed by saline instead of ethanol, it did not alter normal motor 
coordination.  The EC50 of  RJR-2403 was calculated to be 64.5 ng. 
Effect of Acute Intracerebellar DHβE Pretreatment on RJR-2403-induced  
Attenuation of Ethanol Ataxia. Figure 9A shows that the attenuating effect of ICB RJR-
2403 (125 ng) was markedly and dose dependently antagonized by ICB pretreatment 
with α4β2-selective antagonist, DHβE. A significant drug treatment and time interaction 
F(9,104) =10.52, p<0.05 was observed. Treatment with a 500 ng dose of DHβE produced 
maximum and statistically significant antagonism of RJR-2403-induced attenuation of 
ethanol ataxia: 70% at 15 min, 50% at 30 min, 60% at 45 min with p value <0.05. DHβE 
(250 ng) treatment also produced marked reduction but only at 15 min (48%, p<0.05) 
and 30 min (30%, p<0.05). The smallest 125ng dose of DHβE resulted in a small but 
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significant antagonism at 15 min (20%, p< 0.05) only. The EC50 of RJR-2403 in the 
presence of DHβE was calculated to be 184.2 ng. When the order of DHβE and RJR-
2403 administration was switched (i.e. RJR-2403 was microinfused 5 min prior to DHβE 
microinfusion), DHβE failed to antagonize RJR-2403’s attenuating action because the 
animals displayed typical RJR-2403 responses (i.e. attenuation of ethanol ataxia). When 
ICB microinfusion of 500 ng dose of DHβE and RJR-2403 was followed by saline 
injection instead of ethanol, no alteration in the normal motor coordination was observed 
(Fig. 9A DHβE + RJR-2403 + saline, x---x). The data shown in Fig. 9A were also 
expressed as AUC values in Fig. 9B. The AUC analysis clearly demonstrates that with 
increasing doses of DHβE, RJR-2403-induced attenuation of ethanol ataxia was 
markedly reduced and consequently profound ataxia was observed. Thus, the higher the 
bar graph the greater was the degree of ataxia.  
Effect of Acute Intracerebellar DHβE Pretreatment on Nicotine-Induced Attenuation 
of Ethanol Ataxia. To obtain further evidence regarding the role of α4β2 subtype in the 
functional interaction between nicotine and ethanol, we investigated the effect of ICB 
pretreatment with DHβE on nicotine-induced attenuation of ethanol ataxia (Fig. 10A). A 
significant drug treatment and time interaction was observed [F (9,104) = 7.78, p<0.05]. All 
doses (250, 500, 750 ng) of DHβE markedly and dose-dependently decreased nicotine’s 
(5 ng) ability to reduce ethanol ataxia. DHβE (750 ng) treatment resulted in a significant 
reduction in nicotine-induced attenuating action at 15 (78%), 30 (75%) and 45 min (40%), 
respectively with p<0.05. Treatment with 500 ng DHβE produced 63%, 25% decrease in 
nicotine-induced attenuation of ethanol ataxia with p<0.05 at 15 and 30 min, respectively. 
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No change in nicotine-induced action at 45 min was noted as the animals maintained their 
normal motor incoordination. The smallest dose of DHβE (250 ng) produced a 34%  
 
 
 
 
 
 
 
 
FIGURE 8: Effect of intracerebellar (ICB) microinfusion of various doses of α4β2 nicotinic 
acetylcholine receptor subtype selective agonist, RJR-2403, on ethanol (2g/kg, i.p.)-
induced ataxia. Each point represents the mean ± S.E.M. of 8-10 mice. A: ○ aCSF + 
ethanol; ♦ RJR-2403 31 ng + ethanol; ▲ RJR-2403 62 ng + ethanol; ∆ RJR-2403 125 ng + 
ethanol; □ RJR-2403 500 ng + ethanol; x RJR-2403 500ng + Saline. B: The AUC data are 
derived from the same treatment presented above in Fig. 8A; the treatments are shown 
above the appropriate bars. 
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FIGURE 9:  Effect of intracerebellar (ICB) microinfusion of various doses of the α4β2-
selective nicotinic acetylcholine receptor subtype antagonist, DHβE on RJR-2403 (125 ng; 
ICB)-induced attenuation of ethanol (2g/kg, i.p.) ataxia. Each point represents the mean ± 
S.E.M. of 8-10 mice. A: ○ aCSF + ethanol; ● DHβE 500 ng + RJR-2403 + ethanol; □ DHβE 
250 ng + RJR-2403 + ethanol; ▼ DHβE 125 ng + RJR-2403 + ethanol; ■ RJR-2403 + 
ethanol; x DHβE 500 ng + RJR-2403 + Saline. B: The area under the curve (AUC) data 
are derived from the same treatments presented above; the treatments are shown above 
the appropriate bars. 
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(p<0.05) and 15% decrease in nicotine’s attenuating action at 15 and 30 min, respectively. 
There was no change in nicotine-induced attenuation at 45 min post-ethanol administration 
as the animals maintained their normal motor coordination. DHβE was shown to be slightly 
more potent in antagonizing RJR-2403’s action  than nicotine’s. In Fig.10B, the same data 
which was presented in Fig. 10A have been expressed as AUC. DHβE pretreatment dose-
dependently increased ethanol ataxia due to antagonism of nicotine-induced attenuation of 
ethanol ataxia. As such, the higher the dose of DHβE, the greater was the ataxia and the 
height of the bar graph (Fig. 10B). 
Effect of α4 Oligonucleotide treatment on RJR-induced attenuation of Ethanol 
Ataxia  As shown in Fig. 11A pretreatment with α4 nAChR subtype antisense (200nM, 
twice a day) significantly (p<0.05) blocked and virtually abolished RJR-2403-induced 
attenuation of ethanol ataxia. The ability of RJR-2403 to attenuate ethanol-induced 
ataxia was diminished by 54% at 15 min post-ethanol (p<0.05) compared to missense 
treated group (Fig.11A. ■---■ vs.▲---▲) and by 74% (p<0.05) compared to RJR-
2403+ethanol group (Fig. 11A. ■---■ vs. □---□). There was a significant drug treatment 
and time interaction F(6, 72) =12.67, p<0.05. Also, at subsequent times (i.e. 30 and 45 
min) there was a significant (p<0.05) impairment in the ability of RJR-2403 to attenuate 
ethanol ataxia due to antisense treatment versus that of missense. However, antisense 
treated mice regained their normal motor coordination relatively quickly compared to 
aCSF + ethanol treated group. Figure 11B shows the expression of Rotorod data (Fig. 
11A) as AUC.  
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FIGURE 10: Effect of intracerebellar (ICB) microinfusion of various doses of a selective 
antagonist of α4β2 nicotinic acetylcholine receptor subtype, DHβE on (-)-nicotine (5 ng; 
ICB)-induced attenuation of ethanol (2g/kg, i.p.) ataxia. Each point represents the mean ± 
S.E.M. of 8-10 mice.  A: ○ aCSF + ethanol; □ DHβE 750 ng + (-)-nicotine + ethanol; ▼ 
DHβE 500 ng + (-)-nicotine + ethanol; ■ DHβE 250 ng + (-)-nicotine + ethanol; ● (-)-
nicotine + ethanol; x DHβE 500  ng +  (-)-nicotine + Saline. B: The area under the curve 
(AUC) data are derived from the same treatments presented above in A; the treatments 
are shown above the appropriate bars. 
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FIGURE 11: Effect of repeated intracerebellar (ICB) microinfusion of antisense and 
missense (200nM; twice daily for 4 days) selective for the α4 nicotinic acetylcholine 
receptor subtype on RJR-2403 (500ng, ICB)-induced attenuation of ethanol (2g/kg, i.p.) 
ataxia.  Each point represents the mean ± S.E.M. of 10-12 animals. A: ○ aCSF + ethanol; 
■ Antisense + RJR-2403 + ethanol (n=10); ▲Missense x 4days + ethanol (n=6); □ RJR-
2403 + ethanol (n=12). B: The area under the curve (AUC) data are derived from the same 
treatments presented above in A; the treatments are shown above the appropriate bars. 
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Western Blot Experiment 
For comparison of α4 nAChR expression in antisense and missense treated mice 
immunoblot experiments were performed on cerebellar tissue (Fig. 12A). According to our 
data, in contrast to the missense oligonucleotides, antisense oligonucleotides decreased 
α4 protein expression markedly but did not abolish it completely as a faint protein band was  
visible at ~ 70kd in the antisense treatment sample. This was consistent with the Rotorod 
data (Fig. 12A) and may explain the relatively faster recovery of antisense treated animals 
at 30  and 45 min compared to aCSF + ethanol treated group (Fig. 12A ■---■ vs. □---□). 
The peak band intensity in the missense and the antisense sample was 84.33% and 
50.48%, respectively (Fig. 12B). GAPDH loading controls depict quantitatively similar 
protein abundance in each lane of the SDS-PAGE-gel. 
Histology 
Histological examination of coronal sections of cerebellum with cresyl violet stain 
shows no morphological alteration or tissue damage following 4 days of antisense and 
missense treatment (Figs. 13A and B). 
Acute Intracerebellar (ICB) microinfusion of PNU-282987 and Ethanol Ataxia: 
Functional Interaction 
Effect of Acute Intracerebellar PNU-282987 on Ethanol Ataxia. As shown in Fig. 14A, 
ICB administration of PNU-282987 caused almost dose-dependent attenuation of 
ethanol ataxia. Three different doses of PNU-282987, 25ng, 250 ng, 2.5µg, were used in 
order to establish a dose-response relationship between PNU-282987 and the 
attenuation of the ethanol ataxia. A significant (77% and 73%; p<0.05) reduction in  
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FIGURE 12: Western blot showing the significant reduction of α4-subunit expression 
following antisense treatment versus missense treatment (A). The lower panel depicts 
equal loading of the samples by expressing the identical levels of GAPDH protein. The 
relative peak density of corresponding bands is shown in Fig. 12B. 
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FIGURE 13:  Histological photomicrograph of coronal sections of the cerebellum of mice 
treated with missense (A) and antisense (B).  
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ethanol ataxia at 15 min post-ethanol injection, following microinfusion of 250ng and 
2.5µg dose of PNU-282987, respectively, was observed.  At subsequent post-ethanol 
Rotorod evaluation times (30, 45, 60 min), animals exhibited nearly 100% normal motor 
coordination (i.e., walked 180 seconds on the Rotorod). The lowest (25ng) PNU-282987 
dose did not produce any effect on ethanol ataxia at 15 min, however, at the other three 
motor evaluation periods, a modest but pronounced (p<0.05; 33%, 100%, 100%, 
respectively) reduction in ataxia was observed.  Overall, a significant drug treatment and 
time interaction was observed (F(12,132) =11.56, p<0.001).  Figure 14B. represents the 
area under the curve (AUC) data of the same treatment groups as presented in Fig. 14A. 
The AUC correlates well with the degree of ethanol ataxia: the greater the AUC of a 
treatment group, the higher was the degree of ataxia noted. Hence, the AUC for the 
PNU-282987-treated group decreased with the increasing dose of PNU-282987. The 
PNU-282987 25ng + ethanol and aCSF + ethanol control groups exhibited the highest 
AUC. 
Effect of Intracerebellar  Methyllycaconitine Pretreatment on PNU-282987-Induced 
Attenuation of Ethanol Ataxia. To verify that PNU-282987-induced attenuation of 
ethanol ataxia was mediated through the α7 nAChR subtype, mice were pretreated with 
ICB methyllycaconitine, an α7- subtype selective antagonist, followed by ICB PNU-
282987 and systemic ethanol. Figure 15A shows that the effect of a 6 ng dose of 
methyllycaconitine was significant on PNU-282987-induced attenuation of ethanol ataxia. 
The drug treatment and time interaction was found to be significant (F(9,141) = 10.612, 
p<0.001). Pretreatment with methyllycaconitine completely abolished the effect of PNU-
282987 on ethanol ataxia at all four motor evaluation time periods (p<0.05). Thus, the  
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FIGURE 14: The effect of intracerebellar (ICB) microinfusion of α7-subtype selective 
nicotinic acetylcholine receptor agonist, PNU-282987, on ethanol (2g/kg, i.p.)-induced 
ataxia. Each point represents the mean ± S.E.M. of 10 mice. A: ○ aCSF + ethanol; ▼ PNU 
25 ng + ethanol; ▲ PNU 250 ng + ethanol; ■ PNU 2.5 µg + ethanol;  x PNU 2.5 μg + 
Saline. B: The area under the curve (AUC) data are derived from the same treatments 
presented above in A; the treatments are shown above the appropriate bars. 
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dose response curve for  methyllycaconatine + PNU + ethanol treatment was 
comparable to that of aCSF + ethanol control group. However, the methyllycaconitine + 
PNU + saline treatment group did not display any alteration in the normal motor 
coordination. The evaluation of AUC data shows an inverse relationship with the degree 
of ataxia (Fig. 15B). Consequently, the AUC of methyllycaconitine + PNU + ethanol (Fig. 
15A ♦---♦) treatment was markedly greater (i.e., maximum ataxia) compared to 
PNU2.5µg + ethanol (Fig. 15A ∆---∆) or methyllycaconitine + PNU + saline (Fig. 15A x---
x) treatments. 
Effect of Acute Intracerebellar Methyllycaconitine Pretreatment on RJR-2403-
Induced Attenuation of Ethanol Ataxia. To confirm the selectivity of α7 selective 
agonist and antagonist employed, mice were pretreated with 12 or 6 ng dose of α7-
subtype selective antagonist, methyllycaconitine, followed by the administration of α2β4-
selective agonist RJR-2403 (ICB 125ng; Fig. 16A). Pretreatment with the highest (12ng) 
dose of methyllycaconitine was able to partially block (51% with p<0.05) RJR-induced 
attenuation of ethanol-ataxia suggesting that at this high dose, methyllycaconitine lost its 
α7-selectivity and additionally antagonized the α4β2 nAChR subtype (Fig. 16A; ▲---▲). 
At 6ng dose, methyllycaconitine did not alter RJR-2403-induced attenuating action while 
the same dose totally abolished the action of PNU-282987 indicating selective α7 
subtype nAChR blockade at this dose (Fig. 15A). A significant drug treatment and time 
interaction was observed [F(9,119) =17.95, p<0.05]. Figure 16B summarizes the AUC for 
each treatment group used in Fig. 16A, as the degree of ethanol ataxia increased, the 
AUC decreases and vice versa. 
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FIGURE 15: The effect of pretreatment on intracerebellar (ICB) microinfusion of the α7-
subtype selective nicotinic acetylcholine receptor antagonist, methyllycaconitine (MLA; 
6ng) on PNU (2.5µg)-induced attenuation of ethanol (2g/kg, i.p.) ataxia. Each point 
represents the mean ± S.E.M. of 10 mice. A: ○ aCSF + ethanol; ♦ MLA 6 ng + PNU 2.5µg 
+ ethanol; ∆ PNU 2.5 µg + ethanol; x MLA 6 ng + PNU 2.5 µg + Saline. B: The area under 
the curve (AUC) data are derived from the same treatment presented above in A; the 
treatments are shown above the appropriate bars. 
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FIGURE 16: The effect of intracerebellar (ICB) microinfusion of various doses of a 
selective antagonist at the α7 nicotinic acetylcholine receptor subtype, methyllycaconitine 
(MLA) on RJR-2403 (125ng, ICB), a selective agonist at α4β2 nicotinic acetylcholine 
receptor subtype-induced attenuation of ethanol (2g/kg, i.p.) ataxia. Each point represents 
the mean ± SEM of 10 mice. A: ○ aCSF + ethanol; ▲ MLA 12 ng + RJR + ethanol; ▼ MLA 
6 ng + RJR + ethanol; □ RJR + ethanol; x MLA 12ng + RJR + Saline. B: The area under 
the curve (AUC) data are derived from the same treatments presented above in Fig. 16A; 
the treatments are shown above the appropriate bars. 
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Effect of Intracerebellar Methyllycaconitine Pretreatment on Nicotine-Induced 
Attenuation of Ethanol Ataxia. To further strengthen our findings presented in Figs. 14 
and 15, and to provide possible evidence that nicotine-induced attenuation of ethanol 
ataxia as reported previously (Al-Rejaie and Dar, 2006a,b,c) is mediated, at least in part, 
through the α7 nAChR subtype, methyllycaconitine was microinfused as pretreatment 
prior to ICB nicotine administration.  Figure 17A shows the effect of three different doses 
(3, 6, 12ng) of methyllycaconitine on nicotine-induced attenuation of ethanol ataxia. 
There was a dose-dependent reduction in nicotine-induced attenuation of ethanol ataxia 
caused by methyllycaconitine pretreatment. A significant drug treatment and time 
interaction [F(15,182) = 14.01, p<0.001] was observed. The highest dose (12ng) of 
methyllycaconitine used in the present study caused a 74% and 58%  (p<0.05) decrease 
in nicotine-induced attenuation at 15 and 30 min, respectively (Fig.17A ;▲---▲ vs. □---
□). The methyllycaconitine dose of 6 ng produced a 41% and 33% (p<0.05). decrease in 
nicotine-induced attenuation of ethanol ataxia at 15 and 30 min, respectively (Fig. 17A; 
♦---♦ vs. □---□). The 3ng dose of methyllycaconitine lacked any significant effect on 
nicotine’s ability to attenuate ethanol ataxia (Fig. 17A: ∆---∆ vs. □---□). When the highest 
dose of methyllycaconitine was microinfused followed by ICB microinfusion of nicotine 
and saline injection instead of ethanol, there was no change in the normal motor 
coordination, thus precluding the possibility of tonic involvement of the α7 subtype in the 
normal coordination. It also may suggest selectivity of ethanol in its functional interaction 
with nicotine. Therefore, microinfusion of methyllycaconitine + nicotine + saline plays no 
role in the normal motor coordination. Likewise, in Fig. 17B, the AUC of 
methyllycaconitine + nicotine + ethanol treatment group increases with increasing doses  
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FIGURE 17: The effect of intracerebellar microinfusion of various doses of, 
methyllycaconitine (MLA), a selective antagonist at the α7 nicotinic acetylcholine receptor 
subtype, on (-)-nicotine (5ng, ICB)-induced attenuation of ethanol (2g/kg, i.p.) ataxia. Each 
point represents the mean + S.E.M. of 10 mice. A: ○ aCSF + ethanol; ▲ MLA 12 ng + (-)-
nicotine + ethanol; ♦ MLA 6 ng + (-)-nicotine + ethanol; ∆ MLA 3 ng + (-)-nicotine + ethanol;  
□ (-)-nicotine + ethanol;  x MLA 12  ng +  (-)-nicotine + Saline. B: The area under the curve 
(AUC) data are derived from the same treatments presented above in A; the treatments 
are shown above the appropriate bars. 
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of methyllycaconitine to denote occurrence of profound ataxia associated with 
nullification of nicotine-induced attenuation of ethanol ataxia. On the other hand, nicotine 
+ ethanol treatment virtually abolished the ethanol ataxia which correlated with reduced 
AUC. 
Effect of α7 Oligonucleotide treatment on PNU-induced attenuation of Ethanol 
Ataxia  Figure 18A, illustrates the effect of ICB repeated antisense and missense 
oligonucleotide treatment on PNU-282987-induced attenuation of ethanol ataxia. The 
antisense against the α7 nAChR subtype significantly reduced the ability of PNU-282987 
to attenuate ethanol ataxia compared to missense treated control (Fig. 18A; □--□ vs. ▼--
-▼). The effect of the repeated ICB microinfusion of the α7 -subtype antisense was 
maximal at 15 min  post-ethanol administration because the degree of ataxia was 
comparable between the antisense-pretreated animals that received PNU-282987 + 
ethanol treatment and the aCSF + ethanol treated group (Fig. 18A: □--□ vs. ○---○). 
Overall, there was significant drug treatment and time interaction (F(9,119) =17.95, 
p<0.05).  Figure 18B shows the AUC of the same treatment groups as in Fig. 18A. The 
overall AUC of the antisense + PNU-282987+ethanol treated mice was higher than that 
of missense + PNU-282987+ethanol-treated control groups. 
Western Blot Data 
Western blot analysis carried out on cerebellar cortical tissue samples obtained 
from missense control and antisense-treated mice failed to show a significant difference 
between two groups indicating that antisense may have a transient effect on the reduction 
of α7 expression at the cerebellar cortical microinfusion site (Fig. 19). 
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FIGURE 18: The effect of chronic intracerebellar (ICB) microinfusion of antisense (ICB, 
200nM; b.i.d. x 4 days) selective for α7 nicotinic acetylcholine receptor subtype and 
missense on PNU-282987 (250ng, ICB)-induced attenuation of ethanol (2g/kg, i.p.) ataxia. 
Each point represents the mean ± S.E.M. of 10 animals. A: ○ aCSF + ethanol; □ antisense 
200nM b.i.d. x 4 days + PNU + ethanol (n=10); ▼ missense + PNU + ethanol (n=12). B: 
The area under the curve (AUC) data are derived from the same treatment presented 
above in A the treatments are shown above the appropriate bars. 
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FIGURE 19: A: Western blot results showing the levels of α7 expression following 
antisense treatment versus missense control treatment. B: The relative peak density of 
corresponding bands as shown in Fig. 19A. 
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Histology 
Histological examination of coronal sections of cerebellum with cresyl violet stain 
shows no morphological alteration or tissue damage following 4 days of antisense and 
missense treatment (Figs. 20A and B). 
Repeated Intracerebellar Microinfusion of RJR-2403 and Ethanol Ataxia: 
Development of Cross-Tolerance 
Dose-Response Relationship between Repeated Intracerebellar RJR-2403 and 
Acute Ethanol Ataxia. Figure 21A demonstrates the relationship between repeated 
(once daily for 5 days) ICB microinfusion of various doses of RJR-2403, 16 hr after the 
last RJR-2403 microinfusion, on acute ethanol (2g/kg; i.p)-induced motor incoordination. 
As shown in Fig. 21A, RJR-2403 (31, 62 and 125ng) treatment attenuated acute ethanol 
ataxia nearly in a dose-dependent manner. Acute ethanol was administered 16h after 
the last RJR-2403 microinfusion. Animals in the control group received aCSF instead of 
RJR-2403. The 125 ng dose of RJR-2403 produced the largest and statistically 
significant (p< 0.01: 57%) reduction in ethanol ataxia versus ethanol controls at 15 min 
post-ethanol injection (Fig. 21A: ♦--♦ vs. ○---○).  For subsequent  tor evaluation times, 
there was no ataxia observed because all animals regained their normal motor 
coordination (Fig. 21A: ♦--♦ vs. ○---○). There was no significant difference between the 
attenuation response of 31ng and 62ng doses of RJR-2403 at various evaluation time 
points. Only RJR-2403 (62ng) produced a significant 21% (p<0.05) reduction  in ethanol 
ataxia at 15 min. Overall, a significant drug treatment and time interaction was observed 
(F9,107 = 4.43; p< 0.001). Repeated ICB pretreatment with DHβE infused 15 min before  
102 
 
 
 
 
 
 
 
 
 
 
FIGURE 20:  Histological photomicrograph of coronal sections of cerebellum of mice 
treated with missense control (A) and antisense (B) 
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daily RJR-2403 treatment virtually abolished the development of cross-tolerance 
between RJR-2403 (125ng) and acute ethanol ataxia.  As also shown in Fig. 21A, RJR-
2403 (125ng; once daily for 5 days) + saline treatment did not alter normal motor 
coordination. Figure 21B represents AUC data for the same treatment groups presented 
in Fig. 21A. There is a direct relationship between AUC and the degree of ataxia i.e., the 
greater the ataxia the larger is the bar size. Therefore, AUC is largest for aCSF + ethanol 
and RJR-2403 31ng + ethanol treatments but relatively small for both the higher doses 
(125 and 62ng) of RJR-2403 + ethanol.  
Initiation Time for Development of Cross-Tolerance Between Repeated 
Intracerebellar RJR-2403 And Acute Ethanol Ataxia. To determine the time required for 
the onset of cross-tolerance between repeated RJR-2403 and acute ethanol ataxia, RJR-
2403 was microinfused for 1, 2, 3, 5, 7 days (once  daily) followed 16 h later after the last 
RJR-2403 treatment by acute ethanol administration and Rotorod evaluation.  The RJR-
2403 dose of 125 ng was selected in these experiments based  on previously conducted 
dose response study (Fig. 21A). As shown in Fig. 22A, the result of RJR-2403 treatment  
for 2, 3, and 5 days was a significant attenuation of acute ethanol ataxia that indicated the 
development of cross-tolerance at all four Rotorod evaluation time periods. There was a 
significant drug treatment and time interaction (F18, 200 = 3.44; p<0.001).  The reduction in 
ethanol ataxia in the 2, 3, and 5-day RJR-2403 treatment groups was as follows: 2-day 
(30%), 3-day (55%), 5-day (57%) with p<0.01 versus control at 15 min post-ethanol 
administration (Fig. 22A: ♦---♦; ▲---▲; ■---■ vs. ○---○). At 30, 45, and 60 min post-ethanol 
evaluation times the animals virtually regained their normal motor coordination.  There was 
no  significant alteration in ethanol ataxia 16h after single RJR-2403 treatment (1-day) at 
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15 min but significant attenuation at 30, 45 and 60 min post-ethanol was observed (Fig. 
22A: □---□ vs. ▼---▼).  When RJR was microinfused for 7 consecutive days, there was not 
much difference in the results of attenuation of ethanol ataxia between RJR-2403 1-day 
and 7-day treatment groups.  In the control group in which, RJR-2403 was microinfused for 
5 days followed by saline injection instead of ethanol, no change in the normal motor 
coordination was noted (x---x vs. ○---○) .Figure 22B shows the results of the same 
treatment groups that were used in Fig. 22A expressed as AUC. As already stated above, 
the AUC displays a direct relationship with the degree of ataxia. The optimum time for the 
development of cross-tolerance was observed following microinfusion of RJR-2403 (once 
daily) for 5-day and not in 7-day RJR-2403 treatment group. 
Duration of Cross-Tolerance Between Intracerebellar RJR-2403 and Acute Ethanol 
Ataxia. Figure 23 shows the duration of time for which the cross-tolerance between RJR-
2403 and ethanol ataxia remained observable.  Similar to the study for the onset of the 
development of cross-tolerance (Fig. 22), the ICB treatment with RJR-2403 (125 ng; once 
daily for 5 days) was the same.  The animals were challenged with the same test dose of 
acute ethanol at 36, 48 and 72 h after the last ICB microinfusion of RJR-2403.  The results 
indicate that the cross-tolerance lasted nearly 48 h from the last RJR administration 
because at 72 h post-RJR-2403 infusion, no cross-tolerance was apparent.  The Rotorod 
response curve for 72h group overlapped the ethanol control group (Fig. 23A: *----* vs. ○---
○) indicating a complete loss of cross-tolerance. The cross-tolerance between repeated 
RJR-2403 and ethanol ataxia developed maximally at 16h from the last RJR-2403 
microinfusion in a 5-day treatment group: 57% (p<0.05) 
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Figure. 21. The effect of repeated intracerebellar (ICB) microinfusion of RJR-2403 (31, 
62 or 125ng; once daily for 5 days), 16 hrs following the last intracerebellar RJR 
microinfusion, on acute ethanol (2g/kg, ip)-induced ataxia. Each point represents the 
mean ± S.E.M of 10 mice. A: ○ aCSF + Ethanol (2g/kg,i.p.); ■ RJR (31ng) + Ethanol; ▲ 
RJR (62ng) + Ethanol; ♦ RJR (125ng) + Ethanol; × RJR (125ng) + Saline. B: The area 
under the curve (AUC) data are derived from the same treatments presented above in A; 
the treatments are shown above the appropriate bars. 
 
 
 
 
 
 
 
  
107 
 
 
 
 
 
  
108 
 
 
 
 
 
 
 
 
 
 
FIGURE 22: The effect of chronic intracerebellar microinfusion (once daily for 1, 2, 3, 5, or 
7 days) of RJR-2403 (125ng), 16 hrs following the last intracerebellar RJR microinfusion, 
on acute ethanol (2g/kg, ip)-induced motor impairment. Each point represents the mean ± 
S.E.M of 10 mice. A: ○ aCSF + Ethanol (2g/kg,i.p.); □ RJR (once daily for 7 days) + 
Ethanol; ▼ RJR (once daily for 1 days)+Ethanol; ♦RJR (once daily for 2 days) + Ethanol; 
▲ RJR (once daily for 3 days) + Ethanol;  ■ RJR (once daily for 5 days) + Ethanol; × RJR 
(once daily for 7 days) + Saline. B: The area under the curve (AUC) data are derived from 
the same treatment presented above in Fig. A; the treatments are shown above the 
appropriate bars. 
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reduction at 15 min in the degree of ethanol ataxia and complete return to normal motor 
coordination by 30 min post-ethanol (Fig. 23A: ■---■ vs. *---*). When ethanol was 
administered at 36 or 48 h after the last RJR microinfusion, there was still a pronounced 
decrease (66%; p<0.05) in ethanol ataxia at 30 min post-ethanol (Fig. 23A: ●---●; ▲---▲; 
*---*). A significant drug treatment and time interaction was observed (F12,156 114 = 2.99; 
p<0.001).  Figure 23B presents the relationship between AUC and the time lapsed after 
RJR-2403 microinfusion when the cross-tolerance was still observable: the longer the 
time lapsed after RJR-2403 infusion, the larger the AUC and vice versa. 
Effect of Repeated Intracerebellar DHβE on Repeated RJR-2403-induced 
Attenuation of Ethanol Ataxia. To confirm the role of α4β2 subtype in RJR-2403-
induced attenuation of ethanol ataxia (Fig. 24), mice were pretreated with DHβE, a 
selective α4β2 nAChR subtype antagonist for 5 days (once a daily) followed 10 min by 
RJR-2403. Sixteen hours after the last microinfusion, ethanol ataxia was evaluated. It is 
clear from Fig. 24 that DHβE significantly reduced RJR-2403’s response: 75% at 15 min, 
66% at 30 min and 60 % at 45 min with p<0.05. Repeated DHβE + RJR-24-3 did not 
change normal motor coordination when saline was injected instead of ethanol. In Fig. 
24B, the same treatment groups as shown in Fig. 24A are expressed as AUC.  The 
various treatments used are shown over the appropriate bar graphs.  
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FIGURE 23: The effect of repeated intracerebellar (ICB) microinfusion (once daily for 
5days) of RJR-2403 (125ng), 16, 36, 48 or 72 hrs following the last ICB RJR microinfusion, 
on acute ethanol (2g/kg, ip)-induced ataxia. Each point represents the mean ± S.E.M of 10 
mice. A: ○ aCSF + Ethanol (2g/kg,i.p.); * RJR (72hrs) + Ethanol; ▲ RJR (48hrs) + Ethanol; 
● RJR (36hrs) + Ethanol; ■ RJR (16hrs) + Ethanol. B: The area under the curve (AUC) 
data are derived from the same treatments presented above in A; the treatments are 
shown above the appropriate bars. 
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FIGURE 24: The effect of repeated intracerebellar (ICB) microinfusion (once daily for 5 
days) of DHβE (500 ng) followed 10 min later by RJR-2403 (125ng) on acute ethanol 
(2g/kg; i.p.)-induced ataxia. A: ○ aCSF + Ethanol (2g/kg,i.p.); □ DHβE + RJR + Ethanol; ♦ 
RJR +Ethanol; × DHβE + RJR + Saline. Each point represents the mean ± S.E.M of 10 
mice.  B: The area under the curve (AUC) data are derived from the same treatment 
presented above in A; the treatments are shown above the appropriate bars. 
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Repeated Intracerebellar microinfusion of PNU 282987 and Ethanol Ataxia: 
Development of Cross-Tolerance 
Dose-Response Relationship between Chronic Intracerebellar PNU-282987 and 
Acute Ethanol Ataxia.  Shown in Fig. 25A is the dose response relationship between 
repeated ICB PNU-282987 (25ng, 250ng, 2.5µg) treatment and ethanol ataxia that was 
initiated 16 h after the last PNU-282987 microinfusion. When given by ICB microinfusion 
for 3 consecutive days (once daily), PNU-282987 dose dependently diminished acute 
ethanol induced ataxia when the animals were evaluated 16 h after the last treatment 
with PNU-282987.  This indicated the development of cross-tolerance between PNU-
282987 and ethanol ataxia.  The PNU-282987 dose of 2.5µg caused the maximum 
reduction (73%; p<0.05) of ethanol ataxia at 15 min which was an indication of the 
highest degree of cross-tolerance development followed by that  produced by PNU-
282987 250ng dose (41%; p<0.05). The animals in the 2.5µg and 250 ng treatment 
groups regained their normal motor coordination by 30 - 45 min post-ethanol 
administration, respectively. The smallest 25ng dose did result in a significant reduction 
in ethanol ataxia at 30 (42%; p<0.05), 45 (100%), and 60 min (100%) post-ethanol 
administration. A significant drug treatment and time interaction was observed 
(F9,102=7.17; p<0.001). Intracerebellar pretreatment with the α7-selective antagonist, 
methyllycaconitine (6 ng; once daily for 3 days) 10 min prior to ICB microinfusion of 
PNU-282987 nearly abolished the ability of PNU-282987 to induce the development of 
cross-tolerance to ethanol ataxia. The methyllycaconitine + PNU-282987 + saline control 
treatment group did not alter normal motor coordination.  Figure 25B shows the 
expression of the data presented in Fig. 25A as the AUC.  The AUC is directly related to  
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FIGURE 25: The effect of repeated intracerebellar (ICB) microinfusion of PNU-282987 
(25ng, 250ng or 2.5µg; once daily for 3days), 16 hrs following the last ICB PNU-282987 
microinfusion, on acute ethanol (2g/kg, ip)-induced ataxia. Each point represents the mean 
± S.E.M of 10 mice. A: ○ aCSF + Ethanol (2g/kg,i.p.); ▲ PNU 25ng + Ethanol; ■ PNU 
250ng + Ethanol; □ PNU 2.5µg + Ethanol; × PNU 2.5µg + Saline. B: The area under the 
curve (AUC) data are derived from the same treatments presented above in A; the 
treatments are shown above the appropriate bars. 
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degree of ataxia i.e., the greater the degree of ataxia the greater will be the AUC 
associated with decreasing dose of PNU-282987.    
Initiation Time for Development of Cross-Tolerance Between Intracerebellar PNU-
282987 and Acute Ethanol Ataxia. Figure 26A illustrates the time for onset of cross 
tolerance between repeated ICB PNU-282987 microinfusion and acute ethanol ataxia. 
The mice were evaluated 16 h after last microinfusion of PNU (250ng). This dose of 
PNU-282987 was selected based on our acute studies in which both 250 ng and 2.5µg 
doses of PNU-282987 produced nearly the same maximal degree of attenuation of 
ethanol ataxia.   In the present study the dose-response data (Fig. 25A) indicates that 
the 250 ng dose of PNU-282987 is of intermediate potency in attenuating ethanol ataxia. 
A single microinfusion of PNU-282987 (i.e. 1-day treatment group)  caused the greatest 
reduction in ethanol ataxia indicating the onset of cross-tolerance between PNU-282987 
and acute ethanol ataxia (Fig. 26A □---□). However, when the same dose (250 ng) of 
PNU-282987 was repeated (once daily) for 3 and 5 days, the degree of cross-tolerance 
as measured by reduction in ethanol ataxia, started to taper off. There was virtually no 
difference in the degree of cross-tolerance between 3 and 5 days of PNU-282987 
treatment as both caused a 42% and 34% decrease in ataxia at 15 min and about 65% 
at 30  min with p<0.05, respectively.  It is clear from the Fig. 26A that the cross-tolerance 
was maximal after 1 day (single microinfusion) of PNU-282987 treatment. A significant 
drug treatment and time interaction was observed (F9, 115 = 3.09; p<0.001). There was no 
effect of PNU-282987 when a 250 ng dose was microinfused for 3 days followed 16 h 
after the last PNU-282987 treatment  with saline injection instead of ethanol (Fig. 26A  
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*----*).  In Fig. 26B, the same treatment groups as shown in Fig. 26A are expressed as 
AUC.  The various treatments used are shown over the appropriate bar graphs.  
Duration of Cross-Tolerance between Intracerebellar PNU-282987 and Acute Ethanol 
Ataxia. Figure 27A shows the time course of the development of cross-tolerance between 
PNU-282987 and acute ethanol ataxia. The ataxic response of an acute ethanol test dose 
was evaluated at 16, 36, 48, 96 h after a one time only ICB microinjection of 250ng dose of 
PNU-282987. PNU-282987 produced marked attenuation of ethanol ataxia at 16, 36 and 
48 h following its microinfusion versus the aCSF + Ethanol controls. The animals in these 
three groups regained 100% of their normal motor coordination within 30 min post-ethanol 
administration (Fig. 27A: ∆---∆; ▲---▲; *---*). At 96 h post- PNU-282987 microinfusion, the 
animals were totally free of any attenuating effect of PNU-282987 on ethanol ataxia. The 
Rotorod response curve of animals in the 96 h post- PNU-282987 group overlapped the 
ethanol control (Fig. 27A; □---□ vs. ○---○) response curves. Overall, a significant drug 
treatment and time interaction was observed (F12, 135 = 15.5; p< 0.001). Pretreatment with 
hexamethonium (1 µg; ICB) produced a complete blockade in PNU’s effect when 
evaluated 48 h after PNU-282987 microinfusion. As shown in Fig. 27B, AUC is largest for 
aCSF + ethanol and 96 h post PNU-282987 injection there was no attenuation of ethanol 
ataxia. The AUC decreased correspondingly as the time interval between PNU-282987 
microinfusion and acute ethanol ataxia becomes reduced i.e., from 48h to 36 h to 16h. 
Effect of Repeated Intracerebellar Methyllycaconitine on Repeated PNU-282987-
induced Attenuation of Ethanol Ataxia. Figure 28 depicts the effect of pretreatment of 
methyllycaconitine (6 ng), an α7-subtype selective antagonist on PNU-282987-induced  
120 
 
 
 
 
 
 
 
 
FIGURE 26: The effect of repeated intracerebellar (ICB) microinfusion of PNU-282987 
(250ng; once daily for 1, 3 or 5 days), 16 hrs following the last ICB PNU microinfusion, on  
acute ethanol (2g/kg, ip)-induced ataxia. Each point represents the mean ± S.E.M of 10 
mice. A: ○ aCSF + Ethanol (2g/kg,i.p.); ▲ PNU (5 days) + Ethanol; ■ PNU (3 
days)+Ethanol; □ PNU (1days) + Ethanol; × PNU (3D) + Saline. B: The area under the 
curve (AUC) data are derived from the same treatments presented above in A; the 
treatments are shown above the appropriate bars. 
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FIGURE 27: The effect of a single intracerebellar (ICB) microinfusion of PNU-282987 (250 
ng), 16, 36, 48 or 96 hrs following the last ICB microinfusion off PNU, on acute ethanol 
(2g/kg, ip)-induced ataxia. A: ○ aCSF + Ethanol (2g/kg,i.p.); ● Hexamethonium + PNU 
(16hr)+Ethanol; □ PNU (96hrs) + Ethanol; ∆ PNU (48hrs) + Ethanol ; ▲ PNU (36hrs) + 
Ethanol; * PNU (16hrs) + Ethanol. Each point represents the mean ± S.E.M of 10 mice.  B: 
The area under the curve (AUC) data are derived from the same treatment presented 
above in A; the treatments are shown above the appropriate bars. 
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attenuation of ethanol ataxia.  This experiment was performed to confirm the involvement 
of the α7 nAChR subtype in the mediation of the action of PNU-282987 against ethanol 
ataxia (Fig. 28 ) Mice were repeatedly treated with methyllycaconitine for 3 days (once per 
day) followed 10 min later by PNU-282987  and ethanol ataxia was tested 16 h after the  
third microinfusion. As shown in Fig. 28, methyllycaconitine completely abolished the PNU-
282987 -induced attenuation of ethanol ataxia. However, the combination of 
methyllycaconitine + PNU-282987 did not alter normal motor coordination (Fig. 28; x---x). 
In Fig. 28B, the same treatment groups as shown in Fig. 28A are expressed as AUC.  The 
various treatments used are shown over the appropriate bar graphs.  
Effect of Acute Intracerebellar RJR-2403/ PNU-282987 in the Absence or Presence 
of Systemic Ethanol on Cerebellar Nitric Oxide Levels 
Figure 29 shows the changes in the cerebellar cortical in NOx levels due to acute  
ethanol treatment versus saline controls in mouse cerebellar tissue homogenates (Panel 
A). Acute ethanol i.p. significantly reduced the total NOx levels by 44% (p<0.05). Panel B 
illustrates the effect of microinfusion of acute ICB RJR-2403, PNU-282987 each alone and 
in combination with acute ethanol. It is clearly shown that both agonists (RJR-2403, PNU-
282987) resulted in dramatic augmentation of NOx versus contralateral controls: 750% 
(p<0.001) for RJR-2403 and 600% (P<0.01) for PNU-282987 as determined by DAN 
colorimetric method. Concurrent administration of ICB RJR-2403 or PNU-282987 in the 
presence of ethanol did enhance NOx compared with contralateral controls but the values 
were not significant different from the respective agonist alone. Overall a significant 
difference between drug treatment and controls was observed (F5,39=9.41, p<0.000). 
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FIGURE 28:  The effect of repeated intracerebellar (ICB) microinfusion (once daily for 3 
days) of methyllycaconitine (6 ng) followed 10 min later by PNU-282987 (2.5µg) on acute 
ethanol (2g/kg; i.p.)-induced ataxia. A: ○ aCSF + Ethanol (2g/kg,i.p.); ∆ Methyllycaconitine 
+ PNU + Ethanol; □ PNU + Ethanol; × Methyllycaconitine + PNU + Saline. Each point 
represents the mean ± S.E.M of 10 mice.  B: The area under the curve (AUC) data are 
derived from the same treatment presented above in A; the treatments are shown above 
the appropriate bars. 
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FIGURE  29. A: The effect of acute ethanol versus saline challenge on NOx levels on 
the mouse cerebellar homogenates. B: Changes in NOx levels following acute RJR-
2403 (125ng) or PNU-282987 (250ng) alone and in combination with ethanol. Each point 
represents the mean ± S.E.M of 10 mice. *p<0.05 vs. controls. 
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Effect of Repeated Intracerebellar RJR-2403/ PNU-282987 in the Absence or 
Presence of Ethanol on Cerebellar Nitric Oxide Levels 
Figure 30 shows the effect of acute ethanol (Panel A) and of repeated intracerebellar 
RJR-2403 and PNU-282987 alone or in the presence of ethanol (Fig. 30B) on NOx (total 
nitrate + nitrite) levels in mouse cerebellar tissue homogenates. Ethanol (2g/kg;i.p.) 
administration resulted in significant reduction (42%) of NOx (Panel A). On the other 
hand, there was a dramatic increase in NOx levels following RJR-2403 and PNU-282987 
microinfusions.  The cerebellar NOx levels determined flourometrically were markedly 
enhanced (500%) at 16h following ICB RJR-2403 (125ng) and about 800% after PNU-
282987 (250ng) microinfusions (Panel B).  Intracerebellar pretreatment with RJR-2403 or 
PNU-282987 completely prevented the reduction in the cerebellar NOx due to ethanol.  
The basal concentration of NOx was measured following ICB microinfusion of aCSF. 
Immunohistochemical Localization of α4 and α7 Subtypes in Mouse Cerebellum 
Figure 31 depicts the localization of the two subtypes of nAChRs, α4 and α7, within 
the cerebellar cortex.  Immunoreactivity for both the α4 and α7 nAChR subtypes in the 
molecular and Purkinje cell layers of the cerebellar cortex was moderate. The expression 
pattern of both subtypes appeared identical at these sites with α4 levels being slightly 
denser than those of α7. The immunochemical data demonstrated relatively low α4 and α7 
staining in granule layer (Fig. 31). 
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FIGURE 30. A: The effect of acute ethanol or saline challenge on NOx levels versus 
aCSF/or contra-lateral controls on mouse cerebellar homogenates. B: The changes in 
NOx levels following 16 h of repeated RJR-2403 (125ng; ICB, once daily for 5 days) or 
PNU (250ng; ICB, once daily for 3 days) alone and in combination with ethanol are 
shown. Each point represents the mean ± S.E.M of 10 mice. *p<0.05 vs. controls. 
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FIGURE 31: Immunohistochemcial localization of α4 (a,b)and α7 (c,d) subtypes in mouse 
cerebellum.  
 
 
 
 
 
 
 
 
 
 
 
    
133 
 
 
 
 
 
 
 
                         
 
 
 
 
 
 
 
CHAPTER FOUR: DISCUSSION 
 
It is of grave concern to public health authorities that two highly addictive 
psychoactive drugs (i.e. nicotine and ethanol) are widely abused together in many 
societies (Romberger and Grant, 2004; Room, 2004). This tendency toward co-abuse 
leads to higher mortality and morbidity rates in co-abusers than that observed for either 
drug alone. This fact demands a thorough understanding of the mechanisms implicated in 
co-addiction and requires investigating the inter-active relationship between the two 
substances of abuse.  
Earlier work in this laboratory revealed that ICB microinfusion of nicotine markedly 
and dose-dependently attenuated ethanol ataxia.  The functional interaction between the 
two psychoactive substances was noted when nicotine was administered acutely (Dar et 
al., 1993, 1994; Al-Rejaie and Dar, 2006a) as well as repeatedly (Al-Rejaie and Dar, 
2006b). We also report the participation of the cerebellar NO system in mediating or 
antagonizing ethanol ataxia. This dissertation research, in extension of an earlier work, 
investigates the participation of two predominant nAChR sutbypes α4β2 and α7  in 
mediating of nicotine’s attenuation of ethanol ataxia.  Achievement of this goal was 
accomplished by modulating the nAChR subtype α4β2 and α7 function using selective 
subtype agonists and antagonists in acute as well as repeated treatment paradigms. The 
correlation of cerebellar NOx levels with ethanol ataxia and its attenuation was also 
established in this project.  
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Behavioral Interaction Between Acute α4β2 and α7  Selective Drugs and Ethanol 
Ataxia  
 Role of α4β2 subtypes. We have previously demonstrated that a marked attenuation of 
ethanol ataxia occurred following ICB microinfusion of nicotine which suggested a 
functional interaction between nicotine and ethanol (Al-Rejaie and Dar, 2006a,b,c; Dar et 
al., 1993, 1994).  The functional interaction between these two psychoactive drugs was 
observed following acute and chronic ICB microinfusion of nicotine (Al-Rejaie and Dar, 
2006b,c).  
   The first aim of the study was to delineate the role of cerebellar α4β2 subtype (the 
most abundant subtype of nAChR system) in nicotine-induced modulation of ethanol 
ataxia. The nAChR α4β2-selective agonist, RJR-2403, like nicotine, markedly attenuated 
motor impairment due to ethanol in a dose-dependent manner which indicated a role of 
α4β2 subtype in nicotine-ethanol functional interaction.  The dose-dependency of RJR-
2403’s action presumably is reflective of its selective action at the α4β2 subtype. When 
given alone, RJR-2403 neither altered the normal motor coordination nor produced any 
overt behavioral hyperactivity. Further evidence for the involvement of α4β2 subtype in the 
functional interactions between nicotine and ethanol was provided by the results of 
experiments in which DHβE was used as an ICB pretreatment.  Pretreatment with DHβE, a 
selective α4β2 antagonist, blocked the attenuation by RJR-2403 of ethanol ataxia.  This 
indicates that attenuation of ethanol ataxia is an α4β2 nAChR subtype-mediated 
phenomenon and that the α4β2 subtype is an important participating factor in the functional 
interaction between nicotine and ethanol.  The ability of DHβE to block the attenuating 
effect of the RJR-2403 in a dose-dependent fashion strongly suggests an involvement of 
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α4β2 subtype in nicotine-ethanol interaction.  Nevertheless, DHβE was unable to prevent 
the attenuating action of RJR-2403 when the order of administration of both drugs was 
reversed (i.e., RJR-2403 is administered prior to DHβE microinfusion). This result is most 
likely because DHβE is a competitive α4β2 antagonist (Damaj et al., 1995b) and may 
compete with RJR-2403 for the same binding sites. Therefore, whichever drug is 
administered first occupies the binding sites and prevents the binding of other drug. This 
phenomenon may be consistent with the observed dose-dependency of DHβE in the 
attenuation of RJR-2403 action. 
The hypothesis that α4β2 subtype plays an important role in the mediation of the 
functional interaction between the two psychoactive drugs was further supported by the 
results of DHβE + nicotine Rotorod experiments. The ICB microinfusion of nicotine 
markedly attenuated ethanol ataxia, with the highest (5 ng) dose virtually abolishing 
ethanol ataxia (Fig. 10).  Interestingly, however, following ICB pretreatment with DHβE, 
interestingly we observed a dose-related marked antagonism of nicotine-induced 
attenuation of ethanol ataxia.  This observation supports the view that nicotine-induced 
attenuation of ethanol ataxia was, in fact, mediated through nAChR of the α4β2 subtype. 
Since the highest dose of DHβE completely abolished the attenuating effect of nicotine on 
ethanol-induced ataxia, it may also suggest a primary role of α4β2 subtype in the functional 
interaction between nicotine and ethanol.  The response curve of DHβE (750 ng) + 
nicotine in the presence of ethanol was nearly identical to that of aCSF + ethanol group 
(Fig. 10).   
In a previously reported study (Al-Rejaie and Dar, 2006a,b,c), the attenuating 
effect of ICB nicotine on ethanol-indcued ataxia was observed only when nicotine was 
137 
 
microinfused first, followed by ethanol administration, and not vice versa.  However, in the 
present investigation RJR-2403 was found to be equally effective in attenuating the 
ethanol-induced ataxia regardless of the order of its microinfusion and ethanol injection.  
There was no difference in the response curves of RJR-2403 + ethanol and ethanol + 
RJR-2304.  Thus, in the case of nicotine the initial activation of nAChRs tantamount to a 
“priming effect” was essential to counter ethanol ataxia because nicotine was ineffective 
when administered post-ethanol. The previous observation (Al-Rejaie and Dar, 2006a) that 
nicotine must be administered first in order to observe its attenuating effect on ethanol 
ataxia and that it was totally ineffective when given post-ethanol administration may 
suggest that nicotine perhaps exerts a “priming” effect on the downstream signaling 
pathways that eventually results in elimination of the ataxic effect of ethanol. On the other 
hand, RJR-2403 did reverse ethanol ataxia whether injected pre- or post-ethanol.  At 
present, we do not have an explanation for the observed difference between nicotine and 
RJR-2403.   It is plausible that by giving ethanol first instead of nicotine; ethanol produces 
well known membrane fluidization.  The latter membrane effect can alter the membrane 
functions and may change the microenvironment to the extent that nicotine by virtue of its 
different chemical structure and perhaps pharmacokinetic properties from RJR-2403 was 
unable to activate its receptors. 
Finally, additional evidence in support of the role of α4β2 subtype in the functional 
interaction between nicotine and ethanol was provided by the results of the Rotorod 
experiments using antisense and missense oligonucleotides against α4β2 subtype of 
nAChR. Nicotinic acetylcholine receptor subtype α4β2 antisense oligonucleotide hybridizes 
with target mRNA and results in protein-specific translation arrest (Bitner et al., 2000).  
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This action was the basis to obtain direct evidence in further support of our hypothesis that 
α4β2 subtype primarily mediates the functional interaction between nicotine and ethanol. 
We relied on an already published phosphorothioate-modified oligonucleotides 
corresponding to the initial 5′ nucleotide residues (2-21) of the rat α4 subunit (Bitner et al., 
2000).  After antisense treatment, RJR-2403 was unable to attenuate ethanol ataxia. This 
observation served the dual purpose to: (i) indicate the effectiveness of antisense; and: (ii) 
confirm that the nAChR α4β2 subtype mediates the nicotine-induced attenuation of ethanol 
ataxia.  The effectiveness of antisense was also confirmed by the observation of a 
significant decrease in α4 receptor protein expression based on Western blot data vs. 
missense treatment (Fig. 12).  Therefore, the Rotorod data with RJR-2403 demonstrating 
an involvement of the α4β2 subtype in the nicotine – ethanol functional interaction was in 
agreement with the antisense oligonucleotide/Western blot data confirming the important 
participation of nAChR subtype α4β2 in the nicotine and ethanol functional interaction.   
The antisense oligonucleotide-treated mice recovered from ethanol-induced ataxia 
relatively sooner following microinfusion of RJR-2403 than the control aCSF + ethanol 
treated mice (with no oligonucleotide pretreatment). This result means that the antisense 
treated mice still retained some expression of the α4 subtype and further supported by our 
immunoblot experiments where a faint but much reduced signal of the α4 protein was 
detected after antisense treatment. Despite the fact that we used a dose 10 times higher 
than that reported by Bitner et al, (2000), we were unable to observe any visual or 
histological signs of toxicity. This is probably because they infused drugs i.c.v. from where 
drugs could have permeated the whole brain while we infused drugs/oligonucleotides 
directly into the cerebellar cortex to obtain a localized action. We have previously 
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demonstrated that the diffusion of drug molecules following ICB microinfusion remains 
confined within a 2 mm area from the site of microinfusion (Meng and Dar, 1996). The ICB 
administration of RJR-2403 produced a dose-dependent attenuation of ethanol ataxia 
which exhibited a pharmacological profile nearly identical to that of nicotine. Briefly, this 
part of the project demonstrated that nicotine-induced attenuation of ethanol ataxia is 
primarily mediated by α4β2 subtype.  
Role of α7 subtype. After establishing the role of α4β2 nAChR subtype in nicotine-induced 
reduction of ethanol ataxia, we sought to delineate the role of the α7 nAChR subtype in 
nicotine-ethanol’s functional interaction. And for that we chose PNU-282987, a potent and 
selective α7 nAChR subtype agonist with a Ki value of 27 nM. We observed that ICB 
microinfusion of the α7-selective subtype agonist, PNU-282987, markedly and dose-
dependently antagonized ethanol ataxia. The dose-dependency of the attenuating action 
of PNU-282987 on ethanol ataxia is strongly supportive of a role for α7 subtype nAChR in 
the established observation of nicotine-ethanol functional interaction.  PNU-282987, similar 
to nicotine, significantly attenuated motor impairment due to ethanol administration.  Like 
nicotine, ICB microinfusion of PNU-282987 alone when followed by saline instead of 
ethanol injection failed to alter normal motor coordination or produced little overt behavioral 
hyperactivity.  
   Further evidence for the role of α7 subtype nAChR and the selective action of 
PNU-282987 was provided by the results of the experiments in which pretreatment with α7-
subtype selective antagonist methyllycaconitine, obliterated PNU-282987-induced 
attenuation of ethanol ataxia. However, pretreatment with methyllycaconitine, an α7 
subtype-selective antagonist, did not alter the action of the α4β2 subtype selective agonist, 
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RJR-240 in attenuating ethanol ataxia. The failure of the ICB dose (6 ng; Fig. 16A ▼---▼) 
of methyllycaconitine to block the attenuating effect of RJR-2403 on ethanol ataxia 
demonstrated the relative selectivity of methyllycaconitine as an antagonist of nAChR α7–
subtype at this dose. The results also suggested that at the dose range selected in the 
present study, both methyllycaconitine and PNU-282987 primarily acted at α7 subtype 
containing nAChR (Fig. 16A).  
We also observed that ICB pretreatment of methyllycaconitine significantly 
antagonized nicotine-induced attenuation of ethanol ataxia in a dose-related manner 
suggesting, that at least in part, nicotine-induced attenuation of ethanol ataxia was indeed 
caused through participation of nAChR α7 subtype as well. The highest (12 ng) dose of 
methyllycaconitine virtually abolished the attenuating effect of nicotine indicating the 
significance of the role of α7 subtype nAChR.  However, unlike nicotine which required an 
initial activation/priming of nAChR because it did not exhibit attenuation of ethanol ataxia 
when microinfused after the  administration of ethanol (Al-Rejaie and Dar, 2006a,b,c), 
PNU-282987 exhibited an ability to antagonize the ethanol ataxia irrespective of whether 
ethanol is injected prior to or following ICB microinfusion of PNU-282987 (data not shown).  
This was also true with respect to RJR-2403 which demonstrated antagonism to ataxia 
whether if ethanol was administered before or after ICB microinfusion of RJR-2403 (Taslim 
et al., 2008). It is difficult to provide any plausible explanation for the difference between 
nicotine-ethanol and RJR-2403- or PNU-282987-ethanol interaction. It is probable that 
some pharmacokinetic or structural differences might have accounted for such variation in 
their pharmacological action. It is also proposed that ethanol is known to alter membrane 
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fluidity and thereby may alter nAChR target sites inaccessible to nicotine but not to RJR-
2403 or PNU-282987. 
Further evidence was sought in support of the involvement of the α7 subtype in the 
attenuating the effect of nicotine in ethanol-induced ataxia by the use of antisense and 
missense oligonucleotides against α7 subtype of nicotinic receptor. The antisense 
sequence was complementary to the translation initiation site of the nAChR α7 subtype. 
The oligonucleotide antisense sequence was employed to interrupt the protein synthesis of 
α7 protein. The antisense and the missense were administered as chronic ICB treatment in 
order to observe a possible alteration in the levels of the α7 subtype proteins.  The use of 
α7 oligonucleotide was to knock down mRNA transcript and its resultant α7 protein. 
Following chronic antisense treatment, PNU-282987 was ineffective in overcoming ethanol 
ataxia unlike in animals with missense treatment indicating interruption in α7 subtype 
synthesis. However, PNU-282987’s action returned within 30 min. We were not able to 
observe a significant difference in the α7 subtype protein expression in Western blot 
analyses. It appears that only a slight alteration in α7 protein caused a significant reduction 
in the Rotorod behavioral response at 15 and 30 min post-ethanol administration.  It can 
be speculated that the discrepancy between the results of behavioral and immunoblot 
experiments might be due to nonspecific binding of α7 nAChR antibodies as reported by 
Herber et al. (2004). These investigators tested different commercially available antibodies 
on various brain samples obtained from non-transgenic (α7
+) and null mutant (α7
-) mice. 
They found that α7 antibodies nonspecifically labeled proteins in both samples and that 
there were no perceptible differences in binding pattern between samples from α7
+ and α7
- 
mice. This points towards questionable specificity of commercially available α7 antibodies. 
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Moreover, it is also possible that oligonucleotides were degraded and therefore could not 
reduce α7 protein expression. Unlike α4 oligonucleotides, α7 oligonucleotides produced 
some signs of toxicity (e.g. weight loss, bleeding), which also indicated that these 
oligonuceotides might have produced some tissue damage, although it was not apparent 
in our histological sections. If the latter possibility is true then it is possible that the inability 
of animals to walk after oligonucleotides and PNU-282987 treatment was due to some 
immune related toxicity in the cerebellar cortex rather than due to reduction in α7 protein 
expression. In conclusion, the results of our acute experimental protocol support an 
important role of  α4β2 and α7 nAChR subtypes in the nicotine-induced attenuation of 
ethanol ataxia. 
Behavioral Interaction Between Repeated α4β2 and α7  Selective Drugs  
and Ethanol Ataxia  
Since the nature of abuse of nicotine in the form of cigarette smoking and of 
ethanol as alcoholic beverage is chronic, it was important to investigate the functional 
consequences of the repeated use of these psychoactive substances. It is the co-abuse of 
both drugs that poses the greater challenge to public health care providers. Essentially, 
this constituted the basis of this research project. Our previous work demonstrated the 
development of cross tolerance between repeated ICB nicotine and ethanol ataxia. Thus, 
the second aim of this project was to see if α4β2 and or α7 subtypes of nAChRs are 
important in the development of cross-tolerance between ICB chronic nicotine and acute 
ethanol that we previously observed and reported.  
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Cross-Tolerance between Repeated α4β2 selective agonist, RJR-2403 and Acute 
Ethanol Ataxia. According to the results of our repeated treatment protocol, tolerance 
develops to acute ethanol ataxia in mice repeatedly exposed to RJR-2403 by ICB 
microinfusions. The development of cross tolerance was α4β2 dependent as pretreatment 
with selective antagonists prevented the subtype agonists-induced tolerance to ethanol 
ataxia. Cross-tolerance between RJR-2403 and ethanol ataxia was dose- and time-
dependent: peaked after 5 days of exposure and lasted until 48 h following the last RJR-
2403 microinfusion. The evaluation of ethanol ataxia was performed only 16 h after the last 
RJR-2403 microinfusion. This time period was considered reasonably adequate during 
which RJR-2403 was expected to have been either eliminated from the animal system or 
converted to inactive metabolites.  This time frame was especially appropriate for RJR-
2403 due to its biological half-life of 2 h. Seven days of repeated ICB microinfusion of RJR-
2403 resulted in significantly diminished Rotorod response (i.e., a markedly less 
attenuation of ethanol ataxia was observed). In fact the attenuation of ethanol ataxia was 
so small that the response curve appeared comparable to ethanol control response curve. 
Another interesting observation was that 7 days of RJR-2403 treatment was accompanied 
by abolishment of RJR-2403-induced attenuating effects on ethanol ataxia.  The 
explanation for the observed virtual absence of cross-tolerance following 7 days RJR-2403 
treatment is, most likely, is due to the putative desensitization phenomenon that takes 
place after repeated exposure to nicotine or subtype selective agonists. During the 
desensitization phase, nAChRs are functionally inactive and do not respond to activation 
by agonist. This explains the virtual absence of cross-tolerance in animals that received  
144 
 
RJR-2403 treatment for 7 days. Consequently, we did not observe usual RJR-2403’s 
response to antagonize ethanol ataxia.    
Cross-Tolerance between Repeated α7 Selective Agonist PNU-282789 and Acute 
Ethanol Ataxia. Based on our acute behavioral data indicating that PNU-282789 
attenuated ethanol ataxia, we sought to explore whether repeated PNU-282789 would also 
results in the development of tolerance to acute ethanol ataxia. Following the same 
protocol as was for repeated RJR-2403’s exposure, we observed tolerance did indeed 
develop to ethanol ataxia after PNU-282789 microinfusion. However, the pattern of cross-
tolerance between PNU-282789 and ethanol ataxia was distinct from that developed 
between RJR-2403 and ethanol ataxia. For example, tolerance developed after a single 
microinfusion of PNU-282789 and lasted for 72 h. We evaluated ethanol ataxia 16 hr 
following the last microinfusion of PNU-282789 as we did for RJR-2403 to be certain that 
the parent drug, PNU-282789  would have been eliminated from the animal in this time 
period. Unlike RJR-2403, the biological half life of PNU-282789 was not available from the 
literature. Consequently, it was difficult to speculate whether attenuation of ethanol ataxia, 
16 h after PNU-282789’ infusion represented tolerance or prolonged drug response. As 
pretreatment with methyllycaconitine, an α7–subtype selective antagonist, blocked PNU-
282789-induced attenuation of ethanol ataxia 16 h after the microinfusion, it was plausible 
to believe that PNU-282789’s action reflected tolerance. This effect could be due to the 
fact that the biological half life of methyllycaconitine is 20 min in rodents and within 1-2 h 
methyllycaconitine is completely eliminated from the system (Stegelmeier et al., 2003). 
Thus, even if PNU-282789 had a half life longer than 16 h and remained in the tissues long 
after methyllycaconitine’s elimination, it would have attenuated ethanol ataxia afterwards. 
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However, when microinfusion of PNU-282987 was preceded by methyllycaconitine, the 
cross-tolerance was not observed indicating that PNU-282987-induced action on α7    
subtype was blocked. This also suggested that the half life of PNU-282987 could not have 
been long and must be shorter that 16 h. On the contrary, PNU-282789-elicited tolerance 
required initial activation of the α7 subtype nAChR and would not occur if receptors were 
pre-blocked with a selective α7 antagonist. We also wanted to preclude the possibility of 
involvement of any non-nicotinic mechanism in the development of the cross-tolerance 
between PNU-282987 and ethanol ataxia. Therefore, we pretreated animals with 
hexamethonium followed by PNU-282987 and ethanol. As was observed, hexamethonium 
pretreatment also abolished the development of cross-tolerance between PNU-282987 
and ethanol ataxia thereby confirming that the PNU-282987-induced response was 
mediated by α7 subtype of nAChRs only. Like RJR-2403, the phenomenon of receptor 
desensitization was also observed following repeated treatment. However, unlike RJR-
2403, receptor desensitization was seen relatively quicker (i.e.  after 3 and 5 days of 
repeated PNU-282789’s microinfusion). As a result of desensitization, there was a 
significant reduction in the ability of PNU-282789 to attenuate ethanol ataxia. Thus, 
compared to RJR-2403, PNU-282789-induced desensitization was quicker in onset as 
supported by others (Alkondon and Albuquerque, 1993; Vibat et al., 1995).  
Typically, tolerance represents a gradual cellular adaptive process that requires 
repeated agonist exposure but in some instances it can develop even with single exposure 
of an agonist. For example, Zhang et al. (2000) demonstrated the development of acute 
nicotine tolerance to operant discriminative stimulus in rats and observed the simultaneous 
upregulation of α7 subtype in certain brain regions. Our finding of a relatively rapid cross-
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tolerance development between α7 subtype and ethanol ataxia was therefore, in 
agreement with their report. However, in this case receptor upregulation is less likely to be 
implicated in cross tolerance as receptor upregulation is generally preceded by receptor 
desensitization (Spark and Pandy, 1999). Our data identified the occurrence of cross-
tolerance even before desensitization set in. Thus, we are inclined to suspect that 
activation of some common cellular signaling events (i.e. nitric oxide) between nicotinic 
agonists and ethanol, rather than receptor desensitization or upregulation, as a 
mechanism in the formation of cross tolerance. In our previous work, we characterized the 
development of cross-tolerance between nicotine and ethanol (Al-Rejaie and Dar, 2006b,c) 
and between nicotine, an α4β2 subtype agonist (RJR-2403) and acute ICB ∆
9-
tetrahydrocannabinol (∆9-THC) in mice (Smith and Dar, 2006).  
Localization of α4β2 and α7 Subtype in  Cerebellum  
 
Distribution maps of neuronal nAChR subtypes have been established in several 
species with receptors composed of the α4β2 subtypes identified as the most abundant and 
functionally active subtype. The cerebellum is known to express multiple nAChR “α” 
subtypes including, α2, α4, α5, α6.  However, some controversy exists with respect to the 
presence of the α7 subtype nAChR in cerebellum (Caruncho et al., 1997; Gotti and 
Clementi, 2004; Nashmi and Lester, 2006). Since this dissertation project focused on the 
study of cerebellar α4β2 and α7, subtypes, we  sought to investigate the distribution of these 
subtypes in cerebellum to confirm that the behavioral response of selective α4β2 and α7 
agonists is indeed carried out by the respective subtypes and that they are anatomically 
present. The results of immunohistochemistry experiments revealed that there is moderate 
expression of both subtypes in the molecular and the Purkinge cell layers with some 
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sparse distribution in granule cell layer. Such a pattern of distribution of α4β2 and α7 
subtypes correlated with the Rotorod behavioral data. Others have also found α4 subtype 
in the Purkinje cell layer, granule cells and the deep cerebellar nuclei while α7 subtype was 
more prominently identified in Purkinje cells (Hill et al., 1987; Caruncho et al., 1997; 
Nakayama et al., 1998), thus corroborating our finding. Thus, the  immunohistochemistry 
data does detects the expression of both α4 and α7 subtypes in the cerebellum. The 
behavioral data, as discussed above demonstrated that both of these nAChR subtypes 
participate in behavioral responses we observed in the Rotorod test. 
Cerebellar Nitric Oxide: Role in Functional Interaction between α4β2 and α7 
selective Drugs and Ethanol Ataxia 
Previously, we had elucidated the involvement of cerebellar glutamate-NO-cGMP 
signaling cascade in the functional interaction between nicotine and acute ethanol- or ∆9-
THC-induced ataxia as well as in the development of cross-tolerance between chronic 
nicotine and ethanol (Al-Rejaie and Dar, 2006a,b) and between nicotine, its α4β2 
subtypes and ∆9-THC ataxia using pharmacological studies. The result of the 
pharmacological experiments demonstrated that the ICB microinfusion of NO donors, 
such as sodium nitroprusside, markedly enhanced the attenuating effects of nicotine on 
ethanol ataxia. On the other hand, inhibitors of NO such as S-methylisothiourea, 
significantly decreased the attenuation of ethanol-induced ataxia due to nicotine. The 
results suggested the involvement of cerebellar NO in nicotine and ethanol functional 
interactions. Similarly, the activator of cGMP, isoliquiritigenin,  microinfused into the 
cerebellum significantly increased nicotine-induced attenuation of ethanol ataxia. In 
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contrast, hand, ODQ, an inhibitor of cGMP, markedly decreased nicotine-induced 
attenuation of ethanol ataxia. The results provided evidence for the involvement of NO-
cGMP system in the nicotine and ethanol interaction. Additionally, pretreatment with 
isoliquirtigenin alone attenuated ethanol ataxia. These results led to the development of 
the NO-cGMP signaling hypothesis that states that any increase in the activity of NO-
cGMP considerably increased the attenuating effect of nicotine as well as that of α4β2 
and α7 subtype agonists, thereby virtually abolishing the ethanol ataxia. Ethanol 
administration as well as ICB microinfusion of ∆9-THC markedly inhibited cerebellar NO 
(Al-Rejaie and Dar, 2006a,b; Smith and Dar, 2007). Therefore, in the present research 
investigation, to provide the experimental support for the proposed hypothesis, 
measurement of cerebellar NO was carried out. 
  In the present study, cerebellar NOx levels following acute treatment with RJR-
2403 and PNU-282987 alone or in the presence of ethanol were measured. The NO data 
obtained were in general agreement with our hypothesis (i.e., the functional interaction 
between nicotine and ethanol is modulated by cerebellar NO-cGMP signaling). The 
nicotinic subtype agonists, RJR-2403, PNU-282987, each significantly elevated NOx levels 
compared to aCSF control while acute ethanol administration significantly diminished 
cerebellar NOx concentration (Fig. 29). These changes in the cerebellar NOx levels 
functionally correlate very well with ethanol- induced ataxia and its antagonism by selective 
nAChR subtype agonists.  In other words, the decrease in cerebellar NOx levels by ethanol 
correlated with the observed ethanol ataxia. Whereas the marked attenuation of ethanol 
ataxia by ICB pretreatment with RJR-2403 and PNU-282987 associated well with an 
increase in NOx level due to RJR-2403 and PNU-282987 and/or with their opposition to the 
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NOx lowering effect of acute ethanol. Similar data was obtained with repeated RJR-2403 
and PNU-282987 microinfusion (i.e. elevation of cerebellar NOx levels that persisted at 
least 16 h after the last agonist micoinfusion [Fig. 30]). Chronically elevated levels of NOx 
significantly reversed the acute ethanol-induced fall in NOx levels leading to restoration of 
normal motor coordination.  Thus, it was also implied that NO signaling participates in the 
mediation of cross-tolerance between  RJR-2403 or PNU-282987 and ethanol ataxia. This 
observation was identical to previous work where repeated ICB nicotine also elevated 
cerebellar NOx levels that pertained to attenuation of ethanol ataxia (Al-Rejaie and Dar, 
2006a,b). 
The effect of ethanol on NOS activity is variable with regards to dose and site of 
action (Chandler et al. 1994). According to some reports, ethanol decreases NO release 
and inhibits NOS activity (Chandler et al., 1994; Czapski et al., 2002).  These observations 
suggest that a strong relationship may exist between NO-cGMP cascade and regulation of 
motor coordination in cerebellum. Cerebellar NOS is located in granule and basket cells 
where NO is released to act on Purkinje cells (Fedele et al., 1999).  Both Purkinje and 
granule cells, exhibit strong immunoreactivity for guanylyl cyclase (Ding et al., 2004). Thus, 
NO would stimulate cGMP production in Purkinje cells resulting in decreased Purkinje cell 
firing. Purkinje cells represent the only inhibitory output in the cerebellum and any event 
leading to depression of Purkinje cell firing would cause a decrease in GABAergic 
transmission within the Purkinje cells. Similarly, cellular changes might have occurred 
following nicotine/RJR-2403/PNU-282987 microinfusion as α7 nAChR receptors are 
reportedly located at the mossy cell-granule cell synapse where nicotinic receptor agonists 
mediate glutamate release (Reno et al., 2004).  
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Cellular Mechanisms between Nicotine-Ethanol Functional Interaction 
The motor coordination activities are regulated by a delicate balance between 
GABAergic inhibitory and glutamatergic excitatory signals operating within the cerebellar 
cortical granule and Purkinje cells, respectively, and any disruption this balance can lead 
to loss of motor control. To help explain the underlying mechanism for the functional 
nicotine and ethanol interaction, we suggest that nicotine/RJR-2403/PNU-282987 and 
ethanol modulate excitatory and inhibitory signals in the cerebellum, respectively. The 
observed ethanol-induced motor incoordination and the attenuation of motor incoordination 
by intracerebellar RJR-2403/PNU-282987 microinfusion was the net outcome of whether 
inhibitory or excitatory signals are dominant. Ethanol is known to potentiate GABAergic 
transmission by stimulating Golgi cell firing within the cerebellum (Carta et al., 2004) (Fig. 
32). The GABA release at the Golgi cell-granule cell synapses depresses the firing of 
granule cells which represent the only excitatory neuronal cells within the cerebellum 
(Voogd and Glickstein, 1998). In the absence of adequate excitatory signals this balance is 
shifted in favor of inhibitory signals producing inhibition of Purkinje cells. Therefore, deep 
cerebellar nuclei (DCN), the major output neurons in the cerebellum undergo profound 
inhibition which will result in motor incoordination (i.e., ataxia).  The excitatory 
neurotransmitter glutamate is released by nicotine/RJR-2403/PNU-282987 to significantly 
enhance the firing rate of granule cells (Fig. 32). The parallel fibers of the granule cells 
synapse extensively with the dendritic tree of Purkinje cells. Purkinje cells express voltage-
gated K+ channels and the activation of Purkinje cells activates K+ channels which 
promotes an outward flow of K+ ion and hyperpolarization (Yazdi et al., 2007; Womack et 
al., 2009).  The net effect will be a substantially reduced firing of Purkinje cells. Purkinje  
151 
 
 
 
 
 
 
 
 
 
FIGURE 32:  Proposed schematic diagram of the effects of RJR-2403/PNU-282987 on the 
attenuation of ethanol ataxia in the cerebellar cortex. 
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cells are the largest inhibitory neurons in cerebellum and function to discharge inhibitory 
output to deep  cerebellar nuclei (DCN). Once Purkinje cell-induced inhibitory transmission 
is depressed, the DCN are disinhibited while granule cell-mediated firing will be unopposed 
to further increase rate. The overall effect would be that DCN will fire at a higher rate than 
before which will normalize aberrant motor activities.  
Our results implicate the significance of cerebellar cortex for the action of nicotinic 
receptor compounds to overcome ethanol-induced ataxia, which is mediated by multiple 
sites in the brain including the cerebellum (Al-Rejaie and Dar, 2006a,b), the striatum 
(Meng and Dar, 1996) and the motor cortex (Barwick and Dar, 1998). Based on the 
functional mapping of the cerebellum the site of action of nicotine lies within -6.0 to -6.4 
AP stereotaxic coordinates in  the cerebellar cortex as nicotine’s microinfusion beyond this 
range had no effect on ethanol ataxia. It is fascinating to propose that ICB microinfusion of 
nicotine to such a small site in the anterior lobe (culmen area) of the cerebellum exerts 
such a powerful anti-ethanol effect. Ethanol was always administered systemically (i.p.) 
and therefore, distributed to entire body including the whole brain. There are at least two 
other brain areas (striatum and motor cortex) that are known to mediate ethanol-induced 
ataxia, yet ICB microinfusion of nicotine virtually abolished the ataxia due to ethanol. 
Selectivity of the Drugs Used in this Project 
For the purpose of this project, agents that were highly selective for nicotinic α4β2  
and α7 subtypes were selected to characterize the role of those respective subtype(s) in 
the nicotine-ethanol interaction. For example, RJR-2403 (Fig. 33), a highly selective and 
potent α4β2 receptor agonist, has Ki values of 26nM for α4β2 and 3.6µM for α7 subtype. 
RJR is less potent than nicotine in inducing dopamine release from synpatosomes and in 
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inducing ileum contraction. However, the compound is equipotent to nicotine in improving 
working and reference memory and in activating rat thalamic synaptosomes (Bencherif et 
al., 1996) and less potent in decreasing body temperature, respiration, and increasing 
heart rate and BP (Lippiello et al., 1996). Also, RJR-2403 is more selective for central than 
peripheral α4β2 subtypes. 
DHβE (Fig. 33) is a short acting competitive antagonist with selectivity for α4β2 
subtypes (ki 109nM) (Shafaee et al., 1999) and effectively prevented several actions of 
nicotine including, antinociception, hypolocomotion, motor impairment, hypothermia and 
discriminative stimulus effects but failed to inhibit nicotine-induced seizures in mice (Damaj 
et al., 1995a,b, 1999).  
PNU-282987 (Fig. 34) is a potent, α7-selective agonist (Ki= 26nM) with low 
activity at α1β3 and α3β3 nAChR subtypes (Ki> 60µM). In addition, the compound 
possesses virtually no activity on monoamine, muscarinic, glutamate and GABa 
receptors greater 1µM. However, PNU-282987 does display some affinity for 5HT3 
receptors (Ki=930nM) (Bodnar et al., 2005). In hippocampal slices, PNU-282987 evoked 
whole cell currents that were counteracted by methyllycaconitine. Activation of α7 
transiently increases CREB and ERK phosphorylation, which appears to be a critical 
step required for long term memory consolidation (Bitner et al., 2007). 
Methyllycaconitine (Fig. 34), a natural norditerpenoid alkaloid, is a reversible 
competitive antagonist for homomeric  α7 subtype.  Methyllycaconitine displays about 
100 fold selectivity for α7 (ki=  1.4 nM) than non- α7 subtype (Ward et al., 1990). 
Compared to muscle α7 subtype, neuronal α7 subtype has high affinity for 
methyllycaconitine. Inhibition to α7 subtype, by methyllycaconitine, precipitated  
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FIGURE 33: Chemical structures of RJR-2403, a selective α4β2 nAChR subtype agonist, 
and DHβE, a selective α4β2 selective antagonist 
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withdrawal responses in mice chronically exposed to nicotine (Salas et a., 2007) and 
increased cocaine induced dopamine release in nucleus accumbens. When 
microinfused into the frontal cortex, methyllycaconitine disrupted both working and 
reference memory performance while DHβE  impaired working memory only (Chan et 
al., 2007).  
Most pharmacological agents are known to exhibit selective affinity for certain 
receptors or subtypes within a certain dose range.  Beyond that range their action might 
spill over to other related receptor types. To address this issue and to ensure the 
selectivity of our selected doses for this project, we designed an experiment in which mice 
were pretreated with α7-subtype selective antagonist, methyllycaconitine, followed by 
treatment with the α4β2 selective agonist, RJR-2403, and then ethanol. As shown in Fig. 
16, methyllycaconitine did not block RJR2403-induced attenuation of ethanol ataxia 
indicating that the action of RJR-2403 was probably carried out by α4β2 subtype since 
methyllycaconitine would have prevented had it been mediated by α7 subtype, This was 
also inferred that methyllycaconitine at 6ng displays selective α7 blockade because the 
same methyllycaconitine dose (6ng) completely eliminated the action of PNU-282987 
2.5µg (Fig. 15). We also believe that PNU-282987 92.5µg) exhibited selective α7 response 
only. However, there was no statistically significant difference between the 
pharmacological response to PNU-282987 2.5 µg and PNU-282987 250 ng in acute 
studies.  We continued further experiments with PNU-282987 250ng. On the other hand 
methyllycaconitine 12 ng, interrupted RJR’s action revealing the loss of selectivity at this 
very dose. 
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FIGURE 34: Chemical structures of PNU-282987, a selective α7 nAChR subtype agonist, 
and methyllycaconitine, a selective α7 selective antagonist 
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Clinical Significance of Research 
The present studies demonstrated a functional antagonistic interaction 
between the two most widely consumed psychoactive drugs. The observation of 
nicotine-induced attenuation of ethanol ataxia, and the development of cross tolerance 
between α4β2 and α7 selective agonists and acute ethanol ataxia provides a clue as to 
why the co-addiction or co-dependence occurs between nicotine and ethanol. By 
extrapolating the current animal data to human system it could be speculated that the 
reduction of ethanol-induce impairment in motor coordination or cognition by 
simultaneous smoking provides a motivation for the drinkers to further drink followed 
by more smoking. This trend rapidly builds dependence to both nicotine and ethanol. 
Current clinical protocols for the treatment of alcoholism or smoking alone have low 
success rates and are hampered by high relapse rates due to the mutual dependence 
on both drugs. This requires thorough understanding of the neurobiology of co-
addiction as well as the functional interaction between nicotine and ethanol to identify 
novel therapeutic targets. This research projects delineates the contribution of nAChR 
subtypes (α4β2, α7) in the mediation of functional interaction between nicotine and 
ethanol. Based on the findings of these studies, it is proposed that the 
pharmacological maninpulation of α4β2 and α7 subtypes could dissociate the functional 
relationship between the two drugs and could provide a treatment for co-addiction. 
Moreover, data from this project suggest that selective agonists at nAChR subtypes 
α4β2 and α7 can be used to design future treatments for ethanol  ataxia, which 
accounts for significant number of traffic accidental deaths and disabilities. 
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Conclusion 
The present studies demonstrated that the nicotine-induced attenuation of 
ethanol ataxia is mediated by cerebellar nAChR subtypes α4β2 and α7. Selective 
agonists at α4β2 and α7 subtypes decreased while their antagonists did not change 
ethanol ataxia. The studies also demonstrated the development of cross-tolerance 
between α4β2 and α7 selective agonists and acute ethanol ataxia in repeated treatment 
paradigm. Both subtypes contributed equally significantly in nicotine’s reduction of 
ethanol ataxia, yet there are subtype-related differences in the onset and duration of 
the cross tolerance as well as the desensitization of the subtypes. While α4β2-subtype- 
mediated cross-tolerance was slow in onset and shorter in duration, the α7 subtype- 
induced cros-tolerance developed rapidly and lasted longer. The nitric oxide-cGMP 
signaling was found to be a key regulator of the functional antagonism detected 
between nicotinic drugs and ethanol.  The cerebellar nitrate+nitrite (measured as total 
tissue nitrite; NOx) levels augmented with nicotinic subtype agonists and decreased 
with ethanol, indicating, attenuation and induction of ataxia, respectively.  Consistent 
with our behavioral and biochemical data, both α4β2 and α7 subtypes were found in 
moderate density in cerebellar cortex, with α4β2 expression slightly higher than that of 
the α7. Findings from this project provide further insight into an antagonistic 
relationship between nicotine and ethanol and help explain as to how this functional 
interaction may form the basis for co-addiction. 
Future Directions 
This research projects investigates an important aspect of nicotine-ethanol’s 
functional interaction that is mediated through cerebellar α4β2 and α7 subtypes and 
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that could possibly be a potential underlying factor for co-addiction. In addition to 
cerebellum, striatum and motor cortex are the key brain areas critically involved in 
the regulation of motor coordination. Therefore, future studies might be designed to 
explore if nAChR subtypes α4β2 and α7 in these brain regions mediate nicotine-
ethanol interaction. A recent report by Gotti et al., (2008) has demonstrated the 
role of α6β2 subtype in nicotine-induced hyperlocomotor and dopamine rewarding 
action, implying the possible involvement of α6β2 subtype in reversing the ethanol 
ataxia. Since moderate levels of α6β2 subtypes are also expressed in cerebellum, it 
might be interesting to see if pharmacological manipulation of α6β2 subtype alters 
nicotine-ethanol’s antagonistic interaction in cerebellum or other areas.  Moreover, 
the present studies were based on the hypothesis that nicotine-induced reduction 
of ethanol ataxia might be a contributing factor for co-addiction. However, the 
project was not extended to observe any correlation between ethanol-evoked 
ataxic phase and increase in nicotine self- administration. Any demonstration of 
this type of positive correlation in animal model will further strengthen the current 
hypothesis. 
Finally, this project determined the alterations in nitric oxide levels following 
nicotinic drugs or ethanol administration while the expression levels for NOS were 
not measured. It would be interesting to see if NOS enzyme undergo upregulation 
following chronic nicotinic agonist treatment. 
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Artificial cerebrospinal fluid (aCSF) 
 
NaOH    27.65mM 
KCl    2.55mM 
CaCl2  0.05mM 
MgCl2  0.94mM 
Na2S2O5  0.05mM 
pH  7.4 (adjusted with NaOH) 
Nitrite analysis buffer solution 
 
20mM Tris-HCL buffer and 10mM EDTA (pH 7.4), 100ml 
Weigh 242.28mg Tris (molecular weight 121.14) 
Add 5 ml of 500 mM EDTA 
Add 75 ml distilled H2O (80 ml total volume) 
Add concentrated HCl slowly to pH 7.4 (~4ml) 
Add distilled H2O to volume of 100ml 
 
Nitrite analysis buffer reagents 
 
30mU Nitrate reductase, 100ul sample solution: 
Stock 1: add 200ul distilled H2O to a 10 U vial 
Stock 2: add 970 µl distilled water to 30 µl stock 1 
Use 20 µl stock 2 for each sample 
3uM (molecular weight: 833.4) NADPH, 0.25 µg/100ul sample solution: 
Stock 1: weigh 50 µg NADPH, then dissolve in 1000 µl distilled H2O 
Stock 2: add 750 µl distilled H2O to 250 µl stock 1 
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Use 20 µl stock 2 for each sample 
750 µM Glucose-6-phosphate (G-6-P; molecular weight: 340.1),  
100 µl sample solution: 
Weigh 1.275 mg G-6-P 
Add 1000 µl distilled H2O 
Use 20 µl for each sample 
48 mU Glucose-6-phosphate dehydrogenase (G-6-PDH), 100 µl sample solution: 
Stock 1: add 1000 µl distilled H2O) to a 100 U vial 
Stock 2: add 976 µl distilled H2O to 24 µl stock 1 
Use 20 µl stock 2 for each sample 
2, 3-Diaminoapthalene (DAN) 50ug/1000ul: 
Weigh 50 µg DAN 
Add 1000 µl 0.62 N HCl 
Add 30 µl to each 100 µl sample solution 
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